DFCI Logo
DFCI Logo
Richard M. Stone, MD

Richard M. Stone, MD

Medical Oncology
MAKE AN APPOINTMENT

Contact Information

Office Phone Number

617-632-2168

Fax

617-632-2933

Appointments

617-632-6028 (new)

On This Page

Biography

Richard M. Stone, MD

Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.

Researcher

Physician

Chief of Staff
Director, Translational Research, Adult Leukemia Program
Lunder Family Chair in Leukemia at Dana-Farber
Institute Physician
Professor of Medicine, Harvard Medical School

Centers/Programs

Adult Leukemia Program

Clinical Interests

Leukemias, Myelodysplastic syndromes, Myeloproliferative disorders

Diseases Treated

Board Certification

  • Hematology, 1988
  • Internal Medicine, 1984
  • Medical Oncology, 1987

Fellowship

  • Dana-Farber Cancer Institute, Hematology/Oncology

Residency

  • Brigham and Women's Hospital, Chief Medical Resident
  • Brigham and Women's Hospital, Internal Medicine

Medical School

  • Harvard Medical School

Recent Awards

  • Dana-Farber Cancer Institute Medical Oncology Teaching Award
    2007

Research

    View Dr. Stone’s Research

    Therapy for Acute Leukemias and Related Disorders

    The primary focus of our clinical team is patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative disorders. Our practice is located in the Center for Hematologic Malignancies in the ambulatory clinic at DFCI, but we also see inpatients at Brigham and Women's Hospital. In addition to seeing patients with refractory leukemia and advanced myelodysplasia, we see others with complex or difficult cases who have been referred from outside New England and from other countries. Our goal is to provide the highest level of clinical care and improve the outcome for all patients.Our research involves identifying novel targets involved in the pathophysiology of acute leukemia and myelodysplastic syndrome. Inhibition of the FLT3 tyrosine kinase, for example, may offer benefits in AML patients - especially those whose blasts have an activating mutation in the enzyme - similar to the success of imatinib in the treatment of patients with chronic myeloid leukemia (CML). After conducting several trials with FLT3 inhibitors as single agents in myeloid malignancies, we are now focusing on combining these drugs with chemotherapeutic agents. Our laboratory continues to explore the mechanism of leukemic transformation via mutated FLT3, especially regarding activation of downstream pathways such as protein kinase A or AKT, which may be involved in key aspects of leukemogenesis such as prevention of apoptosis and promotion of self-renewal. Other areas of clinical research include targeted therapy in T cell ALL, based on inhibition of NOTCH activation, a common survival mechanism in such cells; application of intensive "pediatric-type" strategies in adults with ALL; and many novel drugs in AML and MDS including histone deacetylase inhibitors, NEDD-8 inhibitors, HSP90 inhibitors, MEK inhibitors and others.

    Research Departments

    Support my research

    Publications

      View Dr. Stone's Publications

      • Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia. 2024 Mar 27. View in: Pubmed

      • Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia. J Natl Cancer Inst. 2024 Mar 22. View in: Pubmed

      • Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024 Feb 27; 8(4):978-990. View in: Pubmed

      • Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 2024 Feb 20. View in: Pubmed

      • Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602. View in: Pubmed

      • Search for Scalar Leptoquarks Produced via t-Lepton-Quark Scattering in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2024 Feb 09; 132(6):061801. View in: Pubmed

      • Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML. J Clin Oncol. 2024 Feb 07; JCO2301061. View in: Pubmed

      • Search for Inelastic Dark Matter in Events with Two Displaced Muons and Missing Transverse Momentum in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2024 Jan 26; 132(4):041802. View in: Pubmed

      • Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. 2024 02; 38(2):389-392. View in: Pubmed

      • Evidence for the Higgs Boson Decay to a Z Boson and a Photon at the LHC. Phys Rev Lett. 2024 Jan 12; 132(2):021803. View in: Pubmed

      • Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood. 2024 Jan 12. View in: Pubmed

      • Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024 Mar; 38(3):482-490. View in: Pubmed

      • Probing Small Bjorken-x Nuclear Gluonic Structure via Coherent J/? Photoproduction in Ultraperipheral Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2023 Dec 29; 131(26):262301. View in: Pubmed

      • Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia. Blood Adv. 2023 12 26; 7(24):7457-7458. View in: Pubmed

      • FLT(3)-ing about: the search for the best inhibitor. Blood. 2023 12 07; 142(23):1937-1938. View in: Pubmed

      • Untangling Complexities of Acute Myeloid Leukemia Review Series. Acta Haematol. 2024; 147(2):119-121. View in: Pubmed

      • A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66. View in: Pubmed

      • Measurement of the top quark mass using a profile likelihood approach with the lepton + jets final states in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2023; 83(10):963. View in: Pubmed

      • A search for decays of the Higgs boson to invisible particles in events with a top-antitop quark pair or a vector boson in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2023; 83(10):933. View in: Pubmed

      • Observation of t Lepton Pair Production in Ultraperipheral Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2023 Oct 13; 131(15):151803. View in: Pubmed

      • FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged =60 years. Blood Adv. 2023 09 26; 7(18):5354-5358. View in: Pubmed

      • Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023 09 26; 7(18):5234-5245. View in: Pubmed

      • Measurement of the Dependence of the Hadron Production Fraction Ratios f_{s}/f_{u} and f_{d}/f_{u} on B Meson Kinematic Variables in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2023 Sep 22; 131(12):121901. View in: Pubmed

      • Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia. NEJM Evid. 2023 Oct; 2(10):EVIDoa2300074. View in: Pubmed

      • Search for Exotic Higgs Boson Decays H?AA?4? with Events Containing Two Merged Diphotons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2023 Sep 08; 131(10):101801. View in: Pubmed

      • Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing. JCO Oncol Pract. 2024 Feb; 20(2):220-227. View in: Pubmed

      • Observation of Same-Sign WW Production from Double Parton Scattering in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2023 Sep 01; 131(9):091803. View in: Pubmed

      • All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results. Lancet Haematol. 2023 09; 10(9):e706-e707. View in: Pubmed

      • Observation of the Rare Decay of the ? Meson to Four Muons. Phys Rev Lett. 2023 Sep 01; 131(9):091903. View in: Pubmed

      • Measurements of jet multiplicity and jet transverse momentum in multijet events in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2023; 83(8):742. View in: Pubmed

      • Search for Higgs Boson Decay to a Charm Quark-Antiquark Pair in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2023 Aug 11; 131(6):061801. View in: Pubmed

      • Azimuthal correlations in Z +jets events in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2023; 83(8):722. View in: Pubmed

      • Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood Adv. 2023 08 08; 7(15):4019-4023. View in: Pubmed

      • Azimuthal Correlations within Exclusive Dijets with Large Momentum Transfer in Photon-Lead Collisions. Phys Rev Lett. 2023 Aug 04; 131(5):051901. View in: Pubmed

      • Search for Nonresonant Pair Production of Highly Energetic Higgs Bosons Decaying to Bottom Quarks. Phys Rev Lett. 2023 Jul 28; 131(4):041803. View in: Pubmed

      • Search for Higgs Boson and Observation of Z Boson through Their Decay into a Charm Quark-Antiquark Pair in Boosted Topologies in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2023 Jul 28; 131(4):041801. View in: Pubmed

      • Measurements of the Higgs boson production cross section and couplings in the W boson pair decay channel in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2023; 83(7):667. View in: Pubmed

      • Measurement of the mass dependence of the transverse momentum of lepton pairs in Drell-Yan production in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2023; 83(7):628. View in: Pubmed

      • Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leuk Res. 2023 09; 132:107351. View in: Pubmed

      • CMS pythia  8 colour reconnection tunes based on underlying-event data. Eur Phys J C Part Fields. 2023; 83(7):587. View in: Pubmed

      • Probing Heavy Majorana Neutrinos and the Weinberg Operator through Vector Boson Fusion Processes in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2023 Jul 07; 131(1):011803. View in: Pubmed

      • Search for light Higgs bosons from supersymmetric cascade decays in pp collisions at s=13TeV. Eur Phys J C Part Fields. 2023; 83(7):571. View in: Pubmed

      • Measurement of the differential tt¯ production cross section as a function of the jet mass and extraction of the top quark mass in hadronic decays of boosted top quarks. Eur Phys J C Part Fields. 2023; 83(7):560. View in: Pubmed

      • Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. Am J Hematol. 2023 09; 98(9):E233-E236. View in: Pubmed

      • Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. J Geriatr Oncol. 2023 Jul; 14(6):101538. View in: Pubmed

      • Quatramer™ encapsulation of dual-targeted PI3-Kd/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancer. Bioeng Transl Med. 2023 Sep; 8(5):e10541. View in: Pubmed

      • The International Consensus Classification of acute leukemias of ambiguous lineage. Blood. 2023 05 04; 141(18):2275-2277. View in: Pubmed

      • Updates in Risk Stratification in Myelodysplastic Syndromes. Cancer J. 2023 May-Jun 01; 29(3):138-142. View in: Pubmed

      • Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 05; 21(5):503-513. View in: Pubmed

      • Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2023 May; 2(5). View in: Pubmed

      • Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update. Gynecol Oncol. 2023 06; 173:58-67. View in: Pubmed

      • Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials. JCO Oncol Pract. 2023 06; 19(6):e877-e891. View in: Pubmed

      • Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888. View in: Pubmed

      • Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View in: Pubmed

      • Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv. 2023 04 11; 7(7):1279-1285. View in: Pubmed

      • Emergency examination authorities in Queensland, Australia. Emerg Med Australas. 2023 10; 35(5):731-738. View in: Pubmed

      • MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023 03; 615(7954):913-919. View in: Pubmed

      • The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 03; 615(7954):920-924. View in: Pubmed

      • Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clin Cancer Res. 2023 03 01; 29(5):878-887. View in: Pubmed

      • Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Rev. 2023 07; 60:101056. View in: Pubmed

      • North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. View in: Pubmed

      • The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204. View in: Pubmed

      • Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial. Cancer. 2023 04 01; 129(7):1075-1084. View in: Pubmed

      • Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023 03; 98(3):502-526. View in: Pubmed

      • A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. Cancer Discov. 2023 01 09; 13(1):146-169. View in: Pubmed

      • Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023 Jan; 4(1):149. View in: Pubmed

      • An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023 01; 4(1):27-42. View in: Pubmed

      • Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation. Leuk Res. 2023 02; 125:107004. View in: Pubmed

      • Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022 12 22; 140(25):2663-2671. View in: Pubmed

      • Measurements of the associated production of a W boson and a charm quark in proton-proton collisions at s=8TeV. Eur Phys J C Part Fields. 2022; 82(12):1094. View in: Pubmed

      • Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis. Haematologica. 2022 12 01; 107(12):2955-2960. View in: Pubmed

      • Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247. View in: Pubmed

      • High-dimensional genomic feature selection with the ordered stereotype logit model. Brief Bioinform. 2022 11 19; 23(6). View in: Pubmed

      • Consolidation chemotherapy in AML: Are we playing with a full deck of cards? Best Pract Res Clin Haematol. 2022 Dec; 35(4):101408. View in: Pubmed

      • Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leuk Lymphoma. 2023 01; 64(1):188-196. View in: Pubmed

      • High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Adv. 2022 10 11; 6(19):5570-5581. View in: Pubmed

      • The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer Discov. 2022 10 05; 12(10):2392-2413. View in: Pubmed

      • Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022 09 27; 6(18):5345-5355. View in: Pubmed

      • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228. View in: Pubmed

      • TET2-mutant clonal hematopoiesis and risk of gout. Blood. 2022 09 08; 140(10):1094-1103. View in: Pubmed

      • Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res. 2022 11; 122:106942. View in: Pubmed

      • Search for Higgs Boson Pair Production in the Four b Quark Final State in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2022 Aug 19; 129(8):081802. View in: Pubmed

      • Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. 2022 09; 36(9):2218-2227. View in: Pubmed

      • Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers. J Natl Compr Canc Netw. 2022 08; 20(8):915-923.e5. View in: Pubmed

      • BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 07 19; 12(7):110. View in: Pubmed

      • Search for Flavor-Changing Neutral Current Interactions of the Top Quark and Higgs Boson in Final States with Two Photons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2022 Jul 15; 129(3):032001. View in: Pubmed

      • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022 07 14; 140(2):112-120. View in: Pubmed

      • Search for Resonances Decaying to Three W Bosons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2022 Jul 08; 129(2):021802. View in: Pubmed

      • Probing Charm Quark Dynamics via Multiparticle Correlations in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2022 Jul 08; 129(2):022001. View in: Pubmed

      • Controlled variable selection in Weibull mixture cure models for high-dimensional data. Stat Med. 2022 09 30; 41(22):4340-4366. View in: Pubmed

      • First Search for Exclusive Diphoton Production at High Mass with Tagged Protons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2022 Jul 01; 129(1):011801. View in: Pubmed

      • Observation of the B_{c}^{+} Meson in Pb-Pb and pp Collisions at sqrt[s_{NN}]=5.02??TeV and Measurement of its Nuclear Modification Factor. Phys Rev Lett. 2022 Jun 24; 128(25):252301. View in: Pubmed

      • Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv. 2022 06 14; 6(11):3433-3439. View in: Pubmed

      • Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718. View in: Pubmed

      • Observation of B 0?? (2S)K S0p+p- and B s0?? (2S)K S0 decays. Eur Phys J C Part Fields. 2022; 82(5):499. View in: Pubmed

      • Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood Adv. 2022 05 10; 6(9):2835-2846. View in: Pubmed

      • Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica. 2022 05 01; 107(5):1172-1180. View in: Pubmed

      • Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica. 2022 05 01; 107(5):1034-1044. View in: Pubmed

      • Search for low-mass dilepton resonances in Higgs boson decays to four-lepton final states in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2022; 82(4):290. View in: Pubmed

      • Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2022 04 01; 107(4):836-843. View in: Pubmed

      • Using Z Boson Events to Study Parton-Medium Interactions in Pb-Pb Collisions. Phys Rev Lett. 2022 Mar 25; 128(12):122301. View in: Pubmed

      • Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 08; 63(8):1934-1941. View in: Pubmed

      • Search for strongly interacting massive particles generating trackless jets in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2022; 82(3):213. View in: Pubmed

      • Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv. 2022 03 08; 6(5):1371-1380. View in: Pubmed

      • BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. Blood Cancer Discov. 2022 03 01; 3(2):116-135. View in: Pubmed

      • Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol. 2022 03 01; 29(2):63-73. View in: Pubmed

      • Measurement of the Inclusive and Differential Higgs Boson Production Cross Sections in the Decay Mode to a Pair of t Leptons in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2022 Feb 25; 128(8):081805. View in: Pubmed

      • Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2022 02 24; 139(8):1246-1250. View in: Pubmed

      • Search for long-lived particles decaying to leptons with large impact parameter in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2022; 82(2):153. View in: Pubmed

      • SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582. View in: Pubmed

      • NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw. 2022 02; 20(2):106-117. View in: Pubmed

      • Evidence for X(3872) in Pb-Pb Collisions and Studies of its Prompt Production at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2022 Jan 21; 128(3):032001. View in: Pubmed

      • t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2022 01 08; 6(3):818-827. View in: Pubmed

      • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021 12 30; 138(26):2810-2827. View in: Pubmed

      • Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 12 28; 5(24):5536-5545. View in: Pubmed

      • Search for Long-Lived Particles Decaying in the CMS End Cap Muon Detectors in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2021 Dec 24; 127(26):261804. View in: Pubmed

      • Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol. 2022 03; 107:14-19. View in: Pubmed

      • PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv. 2021 12 14; 5(23):5086-5097. View in: Pubmed

      • Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700. View in: Pubmed

      • Measurements of the Electroweak Diboson Production Cross Sections in Proton-Proton Collisions at sqrt[s]=5.02??TeV Using Leptonic Decays. Phys Rev Lett. 2021 Nov 05; 127(19):191801. View in: Pubmed

      • Combined searches for the production of supersymmetric top quark partners in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2021; 81(11):970. View in: Pubmed

      • Author Correction: Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol. 2021 Nov; 22(11):1465. View in: Pubmed

      • Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2021 12; 2(12):1321-1337. View in: Pubmed

      • Recent amendments to Queensland legislation make mental health presentations to hospital emergency departments more difficult to scrutinise. Emerg Med Australas. 2022 Feb; 34(1):130-133. View in: Pubmed

      • Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML? Leuk Lymphoma. 2021 12; 62(14):3318-3319. View in: Pubmed

      • Measurements of angular distance and momentum ratio distributions in three-jet and Z + two-jet final states in pp collisions. Eur Phys J C Part Fields. 2021; 81(9):852. View in: Pubmed

      • Observation of Forward Neutron Multiplicity Dependence of Dimuon Acoplanarity in Ultraperipheral Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2021 Sep 17; 127(12):122001. View in: Pubmed

      • Precision luminosity measurement in proton-proton collisions at s=13TeV in 2015 and 2016 at CMS. Eur Phys J C Part Fields. 2021; 81(9):800. View in: Pubmed

      • Constraints on the Initial State of Pb-Pb Collisions via Measurements of Z-Boson Yields and Azimuthal Anisotropy at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2021 Sep 03; 127(10):102002. View in: Pubmed

      • Afghan scholars despair after Taliban's takeover. Science. 2021 08 27; 373(6558):948-949. View in: Pubmed

      • Search for charged Higgs bosons produced in vector boson fusion processes and decaying into vector boson pairs in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2021; 81(8):723. View in: Pubmed

      • Fc?R engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity. Nat Commun. 2021 08 09; 12(1):4791. View in: Pubmed

      • Search for a heavy vector resonance decaying to a Z  boson and a Higgs boson in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2021; 81(8):688. View in: Pubmed

      • Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 2022 01; 36(1):210-220. View in: Pubmed

      • Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022 01; 36(1):90-99. View in: Pubmed

      • MUSiC: a model-unspecific search for new physics in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2021; 81(7):629. View in: Pubmed

      • Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861. View in: Pubmed

      • Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787. View in: Pubmed

      • Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. J Hematol Oncol. 2021 07 06; 14(1):107. View in: Pubmed

      • Observation of a New Excited Beauty Strange Baryon Decaying to ?_{b}^{-}p^{+}p^{-}. Phys Rev Lett. 2021 Jun 25; 126(25):252003. View in: Pubmed

      • Measurement of the W? Production Cross Section in Proton-Proton Collisions at sqrt[s]=13??TeV and Constraints on Effective Field Theory Coefficients. Phys Rev Lett. 2021 Jun 25; 126(25):252002. View in: Pubmed

      • Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 12; 35(12):3542-3550. View in: Pubmed

      • A precision medicine classification for treatment of acute myeloid leukemia in older patients. J Hematol Oncol. 2021 06 23; 14(1):96. View in: Pubmed

      • Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 06 03; 137(22):3093-3104. View in: Pubmed

      • Measurements of production cross sections of the Higgs boson in the four-lepton final state in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2021; 81(6):488. View in: Pubmed

      • Fission reactions are smoldering again at Chernobyl. Science. 2021 05 14; 372(6543):670. View in: Pubmed

      • Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 05 01; 106(5):1330-1342. View in: Pubmed

      • Measurement of the Higgs boson production rate in association with top quarks in final states with electrons, muons, and hadronically decaying tau leptons at s=13TeV. Eur Phys J C Part Fields. 2021; 81(4):378. View in: Pubmed

      • After revival, Iran's great salt lake faces peril. Science. 2021 04 30; 372(6541):444-445. View in: Pubmed

      • A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. Blood Adv. 2021 04 27; 5(8):2279-2283. View in: Pubmed

      • Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. Am J Hematol. 2021 07 01; 96(7):E259-E262. View in: Pubmed

      • Development and validation of HERWIG 7 tunes from CMS underlying-event measurements. Eur Phys J C Part Fields. 2021; 81(4):312. View in: Pubmed

      • BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia. Haematologica. 2021 04 01; 106(4):931-932. View in: Pubmed

      • Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223. View in: Pubmed

      • Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803. View in: Pubmed

      • Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci Transl Med. 2021 03 31; 13(587). View in: Pubmed

      • Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. PLoS One. 2021; 16(3):e0249087. View in: Pubmed

      • Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol. 2021 04; 22(4):520-529. View in: Pubmed

      • Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood Adv. 2021 03 09; 5(5):1474-1482. View in: Pubmed

      • Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551. View in: Pubmed

      • Measurements of pp?ZZ production cross sections and constraints on anomalous triple gauge couplings at s=13TeV. Eur Phys J C Part Fields. 2021; 81(3):200. View in: Pubmed

      • Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9. View in: Pubmed

      • Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512. View in: Pubmed

      • Search for dark matter produced in association with a leptonically decaying Z boson in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2021; 81(1):13. View in: Pubmed

      • NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021 01 06; 19(1):16-27. View in: Pubmed

      • Search for top squark pair production using dilepton final states in pp collision data collected at s=13TeV. Eur Phys J C Part Fields. 2021; 81(1):3. View in: Pubmed

      • Measurement of single-diffractive dijet production in proton-proton collisions at s=8Te with the CMS and TOTEM experiments. Eur Phys J C Part Fields. 2020; 80(12):1164. View in: Pubmed

      • Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer Discov. 2021 03; 11(3):626-637. View in: Pubmed

      • Evidence for Top Quark Production in Nucleus-Nucleus Collisions. Phys Rev Lett. 2020 Nov 27; 125(22):222001. View in: Pubmed

      • Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175. View in: Pubmed

      • A Deep Neural Network for Simultaneous Estimation of b Jet Energy and Resolution. Comput Softw Big Sci. 2020; 4(1):10. View in: Pubmed

      • Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021 01 01; 39(1):57-65. View in: Pubmed

      • Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 10 13; 4(19):4945-4954. View in: Pubmed

      • Observation of the Production of Three Massive Gauge Bosons at sqrt[s]=13??TeV. Phys Rev Lett. 2020 Oct 09; 125(15):151802. View in: Pubmed

      • Observation of the B_{s}^{0}?X(3872)? Decay. Phys Rev Lett. 2020 Oct 09; 125(15):152001. View in: Pubmed

      • Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: A multicenter randomized clinical trial. J Vet Intern Med. 2020 Nov; 34(6):2384-2397. View in: Pubmed

      • Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci U S A. 2020 10 20; 117(42):26340-26346. View in: Pubmed

      • Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA. Living Rev Relativ. 2020; 23(1):3. View in: Pubmed

      • Indigenous Alaskans demand a voice in research on warming. Science. 2020 09 11; 369(6509):1284-1285. View in: Pubmed

      • Studies of Charm Quark Diffusion inside Jets Using Pb-Pb and pp Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2020 Sep 04; 125(10):102001. View in: Pubmed

      • Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543. View in: Pubmed

      • Search for physics beyond the standard model in events with jets and two same-sign or at least three charged leptons in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2020; 80(8):752. View in: Pubmed

      • American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 08 11; 4(15):3528-3549. View in: Pubmed

      • Study of central exclusive production in proton-proton collisions at s=5.02 and 13TeV. Eur Phys J C Part Fields. 2020; 80(8):718. View in: Pubmed

      • Measurements of tt[over ¯]H Production and the CP Structure of the Yukawa Interaction between the Higgs Boson and Top Quark in the Diphoton Decay Channel. Phys Rev Lett. 2020 Aug 07; 125(6):061801. View in: Pubmed

      • Siberia's 'gateway to the underworld' hit by heat wave. Science. 2020 08 07; 369(6504):612-613. View in: Pubmed

      • Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer. 2020 11 01; 126(21):4735-4743. View in: Pubmed

      • Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. Leukemia. 2021 04; 35(4):1188-1192. View in: Pubmed

      • Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma. 2020 12; 61(12):2900-2904. View in: Pubmed

      • New tensions dim hopes for salvaging Iran nuclear deal. Science. 2020 06 19; 368(6497):1300-1301. View in: Pubmed

      • Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug; 7(8):e601-e612. View in: Pubmed

      • Mixed higher-order anisotropic flow and nonlinear response coefficients of charged particles in PbPb collisions at sNN=2.76 and 5.02 TeV. Eur Phys J C Part Fields. 2020; 80(6):534. View in: Pubmed

      • Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged?<60 years. Leukemia. 2020 12; 34(12):3215-3227. View in: Pubmed

      • Measurement of the Jet Mass Distribution and Top Quark Mass in Hadronic Decays of Boosted Top Quarks in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2020 May 22; 124(20):202001. View in: Pubmed

      • Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020 05 12; 4(9):1894-1905. View in: Pubmed

      • Measurement of differential cross sections and charge ratios for t-channel single top quark production in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2020; 80(5):370. View in: Pubmed

      • A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1711-1721. View in: Pubmed

      • Constraints on the ?_{c1} versus ?_{c2} Polarizations in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2020 Apr 24; 124(16):162002. View in: Pubmed

      • Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. J Med Chem. 2020 04 23; 63(8):4256-4292. View in: Pubmed

      • Search for a Narrow Resonance Lighter than 200 GeV Decaying to a Pair of Muons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2020 Apr 03; 124(13):131802. View in: Pubmed

      • A multi-dimensional search for new heavy resonances decaying to boosted WW , WZ , or ZZ boson pairs in the dijet final state at 13  Te. Eur Phys J C Part Fields. 2020; 80(3):237. View in: Pubmed

      • Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr; 7(4):e309-e319. View in: Pubmed

      • Search for direct pair production of supersymmetric partners to the t lepton in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2020; 80(3):189. View in: Pubmed

      • Optimal therapeutic strategies for mixed phenotype acute leukemia. Curr Opin Hematol. 2020 Mar; 27(2):95-102. View in: Pubmed

      • Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020 02 25; 4(4):696-705. View in: Pubmed

      • AML: New Drugs but New Challenges. Clin Lymphoma Myeloma Leuk. 2020 06; 20(6):341-350. View in: Pubmed

      • Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 02 13; 135(7):463-471. View in: Pubmed

      • Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leuk Lymphoma. 2020 06; 61(6):1455-1464. View in: Pubmed

      • Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184. View in: Pubmed

      • Search for production of four top quarks in final states with same-sign or multiple leptons in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2020; 80(2):75. View in: Pubmed

      • Search for Supersymmetry with a Compressed Mass Spectrum in Events with a Soft t Lepton, a Highly Energetic Jet, and Large Missing Transverse Momentum in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2020 Jan 31; 124(4):041803. View in: Pubmed

      • Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020 01 30; 135(5):371-380. View in: Pubmed

      • Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Adv. 2020 01 28; 4(2):239-251. View in: Pubmed

      • Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncol Pract. 2020 06; 16(6):e464-e475. View in: Pubmed

      • Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980. View in: Pubmed

      • Measurement of electroweak production of a W boson in association with two jets in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2020; 80(1):43. View in: Pubmed

      • The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156. View in: Pubmed

      • Need for speed. Science. 2020 01 10; 367(6474):134-138. View in: Pubmed

      • Extraction and validation of a new set of CMS pythia8 tunes from underlying-event measurements. Eur Phys J C Part Fields. 2020; 80(1):4. View in: Pubmed

      • Searches for physics beyond the standard model with the MT2 variable in hadronic final states with and without disappearing tracks in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2020; 80(1):3. View in: Pubmed

      • U.S. military tests radiation belt cleanup in space. Science. 2020 01 03; 367(6473):9-10. View in: Pubmed

      • Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250. View in: Pubmed

      • Search for Physics beyond the Standard Model in Events with Overlapping Photons and Jets. Phys Rev Lett. 2019 Dec 13; 123(24):241801. View in: Pubmed

      • Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133. View in: Pubmed

      • Search for Low-Mass Quark-Antiquark Resonances Produced in Association with a Photon at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Dec 06; 123(23):231803. View in: Pubmed

      • Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. Leuk Res Rep. 2019; 12:100189. View in: Pubmed

      • Measurements of triple-differential cross sections for inclusive isolated-photon+jet events in pp collisions at s=8TeV. Eur Phys J C Part Fields. 2019; 79(11):969. View in: Pubmed

      • Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. Blood. 2019 Nov 13; 134(Supplement_1):33. View in: Pubmed

      • Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood. 2019 Nov 13; 134(Supplement_1):15. View in: Pubmed

      • Measurement of the average very forward energy as a function of the track multiplicity at central pseudorapidities in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(11):893. View in: Pubmed

      • Search for new physics in top quark production in dilepton final states in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(11):886. View in: Pubmed

      • Obscure Cold War nerve agents set to be banned. Science. 2019 10 25; 366(6464):404-405. View in: Pubmed

      • Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020 01; 11(1):107-113. View in: Pubmed

      • Search for Subsolar Mass Ultracompact Binaries in Advanced LIGO's Second Observing Run. Phys Rev Lett. 2019 Oct 18; 123(16):161102. View in: Pubmed

      • Search for a Light Charged Higgs Boson Decaying to a W Boson and a CP-Odd Higgs Boson in Final States with eµµ or µµµ in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Sep 27; 123(13):131802. View in: Pubmed

      • Azimuthal separation in nearly back-to-back jet topologies in inclusive 2- and 3-jet events in pp collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(9):773. View in: Pubmed

      • Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. Leukemia. 2020 02; 34(2):358-368. View in: Pubmed

      • Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629. View in: Pubmed

      • Measurement of exclusive ?7700  photoproduction in ultraperipheral pPb collisions at sNN=5.02Te. Eur Phys J C Part Fields. 2019; 79(8):702. View in: Pubmed

      • Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. Haematologica. 2020 03; 105(3):721-729. View in: Pubmed

      • Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 11 01; 25(21):6524-6531. View in: Pubmed

      • Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019 08 01; 381(5):432-443. View in: Pubmed

      • Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 09 12; 134(11):867-879. View in: Pubmed

      • Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501. View in: Pubmed

      • Studies of Beauty Suppression via Nonprompt D^{0} Mesons in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2019 Jul 12; 123(2):022001. View in: Pubmed

      • Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852. View in: Pubmed

      • Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019; 10:2040620719860645. View in: Pubmed

      • Tests of General Relativity with GW170817. Phys Rev Lett. 2019 Jul 03; 123(1):011102. View in: Pubmed

      • Search for a heavy pseudoscalar boson decaying to a Z and a Higgs boson at s=13Te. Eur Phys J C Part Fields. 2019; 79(7):564. View in: Pubmed

      • North Korea's HIV epidemic emerges from the shadows. Science. 2019 06 28; 364(6447):1215-1216. View in: Pubmed

      • Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687. View in: Pubmed

      • High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019 08; 94(8):921-928. View in: Pubmed

      • Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721. View in: Pubmed

      • Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019 07 25; 134(4):374-382. View in: Pubmed

      • Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. Mol Cancer Ther. 2019 08; 18(8):1451-1459. View in: Pubmed

      • Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 06 01; 17(6):721-749. View in: Pubmed

      • Search for supersymmetry in events with a photon, jets, b -jets, and missing transverse momentum in proton-proton collisions at 13 Te. Eur Phys J C Part Fields. 2019; 79(5):444. View in: Pubmed

      • Combined measurements of Higgs boson couplings in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(5):421. View in: Pubmed

      • Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019 11; 33(11):2599-2609. View in: Pubmed

      • Measurement of the tt¯ production cross section, the top quark mass, and the strong coupling constant using dilepton events in pp collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(5):368. View in: Pubmed

      • Search for vector-like quarks in events with two oppositely charged leptons and jets in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(4):364. View in: Pubmed

      • Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res. 2019 06; 29(6):446-459. View in: Pubmed

      • Jet Shapes of Isolated Photon-Tagged Jets in Pb-Pb and pp Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2019 Apr 19; 122(15):152001. View in: Pubmed

      • Search for W Boson Decays to Three Charged Pions. Phys Rev Lett. 2019 Apr 19; 122(15):151802. View in: Pubmed

      • Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica. 2020 01; 105(1):161-169. View in: Pubmed

      • Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385. View in: Pubmed

      • Measurement of the top quark mass in the all-jets final state at s=13TeV and combination with the lepton+jets channel. Eur Phys J C Part Fields. 2019; 79(4):313. View in: Pubmed

      • Observation of Two Excited B_{c}^{+} States and Measurement of the B_{c}^{+}(2S) Mass in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Apr 05; 122(13):132001. View in: Pubmed

      • Observation of Single Top Quark Production in Association with a Z Boson in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Apr 05; 122(13):132003. View in: Pubmed

      • Search for resonant production of second-generation sleptons with same-sign dimuon events in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(4):305. View in: Pubmed

      • Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. J Am Geriatr Soc. 2019 05; 67(5):889-897. View in: Pubmed

      • Combination of Searches for Higgs Boson Pair Production in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Mar 29; 122(12):121803. View in: Pubmed

      • Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402. View in: Pubmed

      • Search for dark matter produced in association with a Higgs boson decaying to a pair of bottom quarks in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(3):280. View in: Pubmed

      • Measurement of exclusive ? photoproduction from protons in p Pb collisions at sNN=5.02TeV. Eur Phys J C Part Fields. 2019; 79(3):277. View in: Pubmed

      • Measurement of associated production of a W boson and a charm quark in proton-proton collisions at s=13Te. Eur Phys J C Part Fields. 2019; 79(3):269. View in: Pubmed

      • Search for Narrow H? Resonances in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Mar 01; 122(8):081804. View in: Pubmed

      • Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019 03 07; 176(6):1265-1281.e24. View in: Pubmed

      • Reduced disease severity following therapeutic treatment with angiotensin 1-7 in a mouse model of multiple sclerosis. Neurobiol Dis. 2019 07; 127:87-100. View in: Pubmed

      • Constraining the p-Mode-g-Mode Tidal Instability with GW170817. Phys Rev Lett. 2019 Feb 15; 122(6):061104. View in: Pubmed

      • Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia. 2019 07; 33(7):1620-1634. View in: Pubmed

      • Study of the underlying event in top quark pair production in pp collisions at 13 Te. Eur Phys J C Part Fields. 2019; 79(2):123. View in: Pubmed

      • Search for single production of vector-like quarks decaying to a top quark and a W boson in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(2):90. View in: Pubmed

      • Search for rare decays of Z and Higgs bosons to J/? and a photon in proton-proton collisions at s = 13 TeV. Eur Phys J C Part Fields. 2019; 79(2):94. View in: Pubmed

      • Search for the Higgs Boson Decaying to Two Muons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Jan 18; 122(2):021801. View in: Pubmed

      • A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559. View in: Pubmed

      • Search for Dark Matter Particles Produced in Association with a Top Quark Pair at sqrt[s]=13??TeV. Phys Rev Lett. 2019 Jan 11; 122(1):011803. View in: Pubmed

      • TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 07; 33(7):1747-1758. View in: Pubmed

      • Measurement of differential cross sections for inclusive isolated-photon and photon+jet production in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2019; 79(1):20. View in: Pubmed

      • Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617. View in: Pubmed

      • Observation of Medium-Induced Modifications of Jet Fragmentation in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV Using Isolated Photon-Tagged Jets. Phys Rev Lett. 2018 Dec 14; 121(24):242301. View in: Pubmed

      • Search for Leptoquarks Coupled to Third-Generation Quarks in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Dec 14; 121(24):241802. View in: Pubmed

      • Search for Subsolar-Mass Ultracompact Binaries in Advanced LIGO's First Observing Run. Phys Rev Lett. 2018 Dec 07; 121(23):231103. View in: Pubmed

      • Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 02 14; 133(7):676-687. View in: Pubmed

      • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528. View in: Pubmed

      • Evidence for the Associated Production of a Single Top Quark and a Photon in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Nov 30; 121(22):221802. View in: Pubmed

      • Measurement of differential cross sections for Z boson production in association with jets in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(11):965. View in: Pubmed

      • Studies of Bs2*(5840)0 and Bs1(5830)0 mesons including the observation of the Bs2*(5840)0?B0KS0 decay in proton-proton collisions at s=8TeV. Eur Phys J C Part Fields. 2018; 78(11):939. View in: Pubmed

      • Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549. View in: Pubmed

      • Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112. View in: Pubmed

      • Measurement of the top quark mass with lepton+jets final states using pp collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(11):891. View in: Pubmed

      • Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. Haematologica. 2018 11; 103(11):1758-1759. View in: Pubmed

      • The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence. Gynecol Oncol. 2018 11; 151(2):187-189. View in: Pubmed

      • GW170817: Measurements of Neutron Star Radii and Equation of State. Phys Rev Lett. 2018 Oct 19; 121(16):161101. View in: Pubmed

      • Search for Pair-Produced Resonances Each Decaying into at Least Four Quarks in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Oct 05; 121(14):141802. View in: Pubmed

      • Observation of the Z??l^{+}l^{-} Decay in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Oct 05; 121(14):141801. View in: Pubmed

      • Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer. 2018 12 15; 124(24):4601-4609. View in: Pubmed

      • Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia. 2019 03; 33(3):771-775. View in: Pubmed

      • Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018 12; 32(12):2546-2557. View in: Pubmed

      • Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. J Neuropathol Exp Neurol. 2018 10 01; 77(10):877-882. View in: Pubmed

      • Search for new physics in dijet angular distributions using proton-proton collisions at s=13TeV and constraints on dark matter and other models. Eur Phys J C Part Fields. 2018; 78(9):789. View in: Pubmed

      • Observation of Higgs Boson Decay to Bottom Quarks. Phys Rev Lett. 2018 Sep 21; 121(12):121801. View in: Pubmed

      • What FLT3 inhibitor holds the greatest promise? Best Pract Res Clin Haematol. 2018 12; 31(4):401-404. View in: Pubmed

      • Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML. Cancer Cell. 2018 09 10; 34(3):355-357. View in: Pubmed

      • Renewed sanctions strangle science in Iran. Science. 2018 Sep 07; 361(6406):961. View in: Pubmed

      • Measurement of the Z/?*?tt cross section in pp collisions at s=13TeV and validation of t lepton analysis techniques. Eur Phys J C Part Fields. 2018; 78(9):708. View in: Pubmed

      • Search for third-generation scalar leptoquarks decaying to a top quark and a t lepton at s=13Te. Eur Phys J C Part Fields. 2018; 78(9):707. View in: Pubmed

      • Measurement of the weak mixing angle using the forward-backward asymmetry of Drell-Yan events in pp collisions at 8 TeV. Eur Phys J C Part Fields. 2018; 78(9):701. View in: Pubmed

      • Measurement of charged particle spectra in minimum-bias events from proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(9):697. View in: Pubmed

      • Observation of the ?_{b1}(3P) and ?_{b2}(3P) and Measurement of their Masses. Phys Rev Lett. 2018 Aug 31; 121(9):092002. View in: Pubmed

      • Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018 09; 93(9):1119-1126. View in: Pubmed

      • Elliptic Flow of Charm and Strange Hadrons in High-Multiplicity p+Pb Collisions at sqrt[s_{NN}]=8.16??TeV. Phys Rev Lett. 2018 Aug 24; 121(8):082301. View in: Pubmed

      • Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254. View in: Pubmed

      • Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract. 2019 Sep; 25(6):1349-1356. View in: Pubmed

      • Constraining Gluon Distributions in Nuclei Using Dijets in Proton-Proton and Proton-Lead Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2018 Aug 10; 121(6):062002. View in: Pubmed

      • Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018 07 24; 2(14):1705-1718. View in: Pubmed

      • Application of multi-state models in cancer clinical trials. Clin Trials. 2018 10; 15(5):489-498. View in: Pubmed

      • CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692. View in: Pubmed

      • Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018 07 10; 2(13):1645-1650. View in: Pubmed

      • Measurement of prompt and nonprompt charmonium suppression in PbPb collisions at 5.02 TeV. Eur Phys J C Part Fields. 2018; 78(6):509. View in: Pubmed

      • Search for Physics Beyond the Standard Model in Events with High-Momentum Higgs Bosons and Missing Transverse Momentum in Proton-Proton Collisions at 13 TeV. Phys Rev Lett. 2018 Jun 15; 120(24):241801. View in: Pubmed

      • Observation of tt[over ¯]H Production. Phys Rev Lett. 2018 Jun 08; 120(23):231801. View in: Pubmed

      • Measurement of b hadron lifetimes in pp collisions at s=8TeV. Eur Phys J C Part Fields. 2018; 78(6):457. View in: Pubmed

      • NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia. 2018 12; 32(12):2536-2545. View in: Pubmed

      • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398. View in: Pubmed

      • Search for Heavy Neutral Leptons in Events with Three Charged Leptons in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Jun 01; 120(22):221801. View in: Pubmed

      • Search for the X(5568) State Decaying into B_{s}^{0}p^{±} in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2018 May 18; 120(20):202005. View in: Pubmed

      • Search for Narrow Resonances in the b-Tagged Dijet Mass Spectrum in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2018 May 18; 120(20):201801. View in: Pubmed

      • Search for Tensor, Vector, and Scalar Polarizations in the Stochastic Gravitational-Wave Background. Phys Rev Lett. 2018 May 18; 120(20):201102. View in: Pubmed

      • Measurement of Prompt D^{0} Meson Azimuthal Anisotropy in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2018 May 18; 120(20):202301. View in: Pubmed

      • Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One. 2018; 13(5):e0197049. View in: Pubmed

      • High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825. View in: Pubmed

      • Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol. 2018 05 01; 4(5):686-693. View in: Pubmed

      • Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA. Living Rev Relativ. 2018; 21(1):3. View in: Pubmed

      • Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leuk Lymphoma. 2018 11; 59(11):2723-2726. View in: Pubmed

      • Search for new physics in events with a leptonically decaying Z boson and a large transverse momentum imbalance in proton-proton collisions at s = 13 TeV. Eur Phys J C Part Fields. 2018; 78(4):291. View in: Pubmed

      • Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436). View in: Pubmed

      • Measurement of associated Z + charm production in proton-proton collisions at s=8TeV. Eur Phys J C Part Fields. 2018; 78(4):287. View in: Pubmed

      • Suppression of Excited ? States Relative to the Ground State in Pb-Pb Collisions at sqrt[s]_{NN}=5.02??TeV. Phys Rev Lett. 2018 Apr 06; 120(14):142301. View in: Pubmed

      • Measurement of the Splitting Function in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2018 Apr 06; 120(14):142302. View in: Pubmed

      • Study of dijet events with a large rapidity gap between the two leading jets in pp collisions at s=7TeV. Eur Phys J C Part Fields. 2018; 78(3):242. View in: Pubmed

      • Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 03 07; 10(431). View in: Pubmed

      • GW170817: Implications for the Stochastic Gravitational-Wave Background from Compact Binary Coalescences. Phys Rev Lett. 2018 Mar 02; 120(9):091101. View in: Pubmed

      • Observation of Correlated Azimuthal Anisotropy Fourier Harmonics in pp and p+Pb Collisions at the LHC. Phys Rev Lett. 2018 Mar 02; 120(9):092301. View in: Pubmed

      • Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 02 27; 2(4):444-453. View in: Pubmed

      • Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018 06; 32(6):1338-1348. View in: Pubmed

      • Measurements of the pp?ZZ production cross section and the Z?4l branching fraction, and constraints on anomalous triple gauge couplings at s=13TeV. Eur Phys J C Part Fields. 2018; 78(2):165. View in: Pubmed

      • Observation of Electroweak Production of Same-Sign W Boson Pairs in the Two Jet and Two Same-Sign Lepton Final State in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2018 Feb 23; 120(8):081801. View in: Pubmed

      • Search for standard model production of four top quarks with same-sign and multilepton final states in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2018; 78(2):140. View in: Pubmed

      • Inclusive Search for a Highly Boosted Higgs Boson Decaying to a Bottom Quark-Antiquark Pair. Phys Rev Lett. 2018 Feb 16; 120(7):071802. View in: Pubmed

      • First Search for Nontensorial Gravitational Waves from Known Pulsars. Phys Rev Lett. 2018 Jan 19; 120(3):031104. View in: Pubmed

      • A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert Rev Hematol. 2018 02; 11(2):145-154. View in: Pubmed

      • Observation of Top Quark Production in Proton-Nucleus Collisions. Phys Rev Lett. 2017 Dec 15; 119(24):242001. View in: Pubmed

      • Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017 Dec 14; 17(1):852. View in: Pubmed

      • Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget. 2018 Jan 12; 9(4):4354-4365. View in: Pubmed

      • Search for dark matter produced in association with heavy-flavor quark pairs in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2017; 77(12):845. View in: Pubmed

      • Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):E49-E52. View in: Pubmed

      • Search for Evidence of the Type-III Seesaw Mechanism in Multilepton Final States in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2017 Dec 01; 119(22):221802. View in: Pubmed

      • A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261. View in: Pubmed

      • Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 Nov 09; 377(19):1903. View in: Pubmed

      • Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 11 09; 377(19):1903. View in: Pubmed

      • Measurements of the associated production of a Z boson and b jets in pp collisions at s=8TeV. Eur Phys J C Part Fields. 2017; 77(11):751. View in: Pubmed

      • Measurement of the triple-differential dijet cross section in proton-proton collisions at s=8TeV and constraints on parton distribution functions. Eur Phys J C Part Fields. 2017; 77(11):746. View in: Pubmed

      • Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15; 8(66):109973-109984. View in: Pubmed

      • Search for new phenomena with the MT2 variable in the all-hadronic final state produced in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2017; 77(10):710. View in: Pubmed

      • GW170817: Observation of Gravitational Waves from a Binary Neutron Star Inspiral. Phys Rev Lett. 2017 Oct 20; 119(16):161101. View in: Pubmed

      • Measurement of the B^{±} Meson Nuclear Modification Factor in Pb-Pb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2017 Oct 13; 119(15):152301. View in: Pubmed

      • Search for Supersymmetry in pp Collisions at sqrt[s]=13??TeV in the Single-Lepton Final State Using the Sum of Masses of Large-Radius Jets. Phys Rev Lett. 2017 Oct 13; 119(15):151802. View in: Pubmed

      • GW170814: A Three-Detector Observation of Gravitational Waves from a Binary Black Hole Coalescence. Phys Rev Lett. 2017 Oct 06; 119(14):141101. View in: Pubmed

      • Search for Charged Higgs Bosons Produced via Vector Boson Fusion and Decaying into a Pair of W and Z Bosons Using pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2017 Oct 06; 119(14):141802. View in: Pubmed

      • Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215. View in: Pubmed

      • Which new agents will be incorporated into frontline therapy in acute myeloid leukemia? Best Pract Res Clin Haematol. 2017 12; 30(4):312-316. View in: Pubmed

      • Search for heavy resonances that decay into a vector boson and a Higgs boson in hadronic final states at s=13TeV. Eur Phys J C Part Fields. 2017; 77(9):636. View in: Pubmed

      • Search for Low Mass Vector Resonances Decaying to Quark-Antiquark Pairs in Proton-Proton Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2017 Sep 15; 119(11):111802. View in: Pubmed

      • Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Adv. 2017 Sep 26; 1(21):1786-1789. View in: Pubmed

      • Search for physics beyond the standard model in events with two leptons of same sign, missing transverse momentum, and jets in proton-proton collisions at s=13TeV. Eur Phys J C Part Fields. 2017; 77(9):578. View in: Pubmed

      • Study of Jet Quenching with Z+jet Correlations in Pb-Pb and pp Collisions at sqrt[s]_{NN}=5.02??TeV. Phys Rev Lett. 2017 Aug 25; 119(8):082301. View in: Pubmed

      • Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice? J Oncol Pract. 2017 08; 13(8):471-480. View in: Pubmed

      • Measurement of the jet mass in highly boosted [Formula: see text] events from pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2017; 77(7):467. View in: Pubmed

      • Measurement of double-differential cross sections for top quark pair production in pp collisions at [Formula: see text][Formula: see text] and impact on parton distribution functions. Eur Phys J C Part Fields. 2017; 77(7):459. View in: Pubmed

      • Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044. View in: Pubmed

      • Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06. View in: Pubmed

      • Acute Promyelocytic Leukemia: A Perspective. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):543-544. View in: Pubmed

      • Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 07; 15(7):926-957. View in: Pubmed

      • Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome? J Rheumatol. 2017 07; 44(7):1101-1102. View in: Pubmed

      • Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650. View in: Pubmed

      • Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 08 03; 377(5):454-464. View in: Pubmed

      • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 08 10; 130(6):722-731. View in: Pubmed

      • GW170104: Observation of a 50-Solar-Mass Binary Black Hole Coalescence at Redshift 0.2. Phys Rev Lett. 2017 Jun 02; 118(22):221101. View in: Pubmed

      • Measurement of the top quark mass using single top quark events in proton-proton collisions at [Formula: see text] TeV. Eur Phys J C Part Fields. 2017; 77(5):354. View in: Pubmed

      • Searches for pair production of third-generation squarks in [Formula: see text][Formula: see text] pp collisions. Eur Phys J C Part Fields. 2017; 77(5):327. View in: Pubmed

      • The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. Hematol Oncol Clin North Am. 2017 08; 31(4):663-680. View in: Pubmed

      • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20; 35(24):2745-2753. View in: Pubmed

      • A search for new phenomena in pp collisions at [Formula: see text] in final states with missing transverse momentum and at least one jet using the [Formula: see text] variable. Eur Phys J C Part Fields. 2017; 77(5):294. View in: Pubmed

      • Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica. 2017 08; 102(8):1391-1400. View in: Pubmed

      • Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017 06 15; 129(24):3175-3183. View in: Pubmed

      • Measurement of prompt and nonprompt [Formula: see text] production in [Formula: see text] and [Formula: see text] collisions at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(4):269. View in: Pubmed

      • Relative Modification of Prompt ?(2S) and J/? Yields from pp to PbPb Collisions at sqrt[s_{NN}]=5.02??TeV. Phys Rev Lett. 2017 Apr 21; 118(16):162301. View in: Pubmed

      • Suppression and azimuthal anisotropy of prompt and nonprompt [Formula: see text] production in PbPb collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2017; 77(4):252. View in: Pubmed

      • Measurement of the WZ production cross section in pp collisions at [Formula: see text] and 8[Formula: see text] and search for anomalous triple gauge couplings at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(4):236. View in: Pubmed

      • Directional Limits on Persistent Gravitational Waves from Advanced LIGO's First Observing Run. Phys Rev Lett. 2017 Mar 24; 118(12):121102. View in: Pubmed

      • Observation of Charge-Dependent Azimuthal Correlations in p-Pb Collisions and Its Implication for the Search for the Chiral Magnetic Effect. Phys Rev Lett. 2017 Mar 24; 118(12):122301. View in: Pubmed

      • Upper Limits on the Stochastic Gravitational-Wave Background from Advanced LIGO's First Observing Run. Phys Rev Lett. 2017 Mar 24; 118(12):121101. View in: Pubmed

      • No evidence for microsatellite instability in acute myeloid leukemia. Leukemia. 2017 06; 31(6):1474-1476. View in: Pubmed

      • The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017 10; 31(10):2211-2218. View in: Pubmed

      • A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017 06 15; 129(24):3165-3174. View in: Pubmed

      • Measurement of the [Formula: see text] production cross section using events in the [Formula: see text] final state in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(3):172. View in: Pubmed

      • A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer J. 2017 03 10; 7(3):e542. View in: Pubmed

      • Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566. View in: Pubmed

      • 3 + 7 + FLT3 inhibitors: 1 + 1 ? 2. Blood. 2017 03 02; 129(9):1061-1062. View in: Pubmed

      • Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Curr Opin Hematol. 2017 03; 24(2):139-145. View in: Pubmed

      • The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313. View in: Pubmed

      • Measurement of the production cross section of a W boson in association with two b jets in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2017; 77(2):92. View in: Pubmed

      • A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017 Jan 24; 1(5):331-340. View in: Pubmed

      • Search for Dark Matter and Supersymmetry with a Compressed Mass Spectrum in the Vector Boson Fusion Topology in Proton-Proton Collisions at sqrt[s]=8??TeV. Phys Rev Lett. 2017 Jan 13; 118(2):021802. View in: Pubmed

      • Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017 Mar 30; 129(13):1763-1767. View in: Pubmed

      • Measurements of the [Formula: see text] production cross section in lepton+jets final states in pp collisions at 8 [Formula: see text] and ratio of 8 to 7 [Formula: see text] cross sections. Eur Phys J C Part Fields. 2017; 77(1):15. View in: Pubmed

      • Novel Therapeutics in Acute Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2017; 37:495-503. View in: Pubmed

      • Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):60-87. View in: Pubmed

      • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. View in: Pubmed

      • Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164. View in: Pubmed

      • Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171. View in: Pubmed

      • Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion. 2017 02; 57(2):289-295. View in: Pubmed

      • An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395. View in: Pubmed

      • Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2017 06; 31(6):1278-1285. View in: Pubmed

      • Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours. Nat Cell Biol. 2016 Dec; 18(12):1346-1356. View in: Pubmed

      • Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res. 2017 01 01; 77(1):207-218. View in: Pubmed

      • Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2017 Jan; 176(1):86-91. View in: Pubmed

      • Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leuk Lymphoma. 2017 06; 58(6):1412-1423. View in: Pubmed

      • Thrombosis in AML? Yes, but when to worry? Blood. 2016 10 06; 128(14):1784-1785. View in: Pubmed

      • Measurement of dijet azimuthal decorrelation in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(10):536. View in: Pubmed

      • Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39. View in: Pubmed

      • Measurement of the differential cross section and charge asymmetry for inclusive [Formula: see text] production at [Formula: see text] TeV. Eur Phys J C Part Fields. 2016; 76(8):469. View in: Pubmed

      • Search for direct pair production of supersymmetric top quarks decaying to all-hadronic final states in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(8):460. View in: Pubmed

      • Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. 2016 Aug 16; 7(33):53515-53525. View in: Pubmed

      • Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 10 06; 128(14):1845-1853. View in: Pubmed

      • Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 10; 6(10):1106-1117. View in: Pubmed

      • Measurement of the double-differential inclusive jet cross section in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(8):451. View in: Pubmed

      • Search for new physics in same-sign dilepton events in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(8):439. View in: Pubmed

      • Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol. 2016 Oct; 175(2):226-236. View in: Pubmed

      • Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica. 2016 12; 101(12):1516-1523. View in: Pubmed

      • Search for Resonant Production of High-Mass Photon Pairs in Proton-Proton Collisions at sqrt[s]=8 and 13 TeV. Phys Rev Lett. 2016 Jul 29; 117(5):051802. View in: Pubmed

      • Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2. Leukemia. 2016 11; 30(11):2254-2258. View in: Pubmed

      • Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504. View in: Pubmed

      • Measurement of the [Formula: see text] cross section in pp collisions at [Formula: see text] TeVand limits on anomalous gauge couplings. Eur Phys J C Part Fields. 2016; 76(7):401. View in: Pubmed

      • Search for Narrow Resonances in Dijet Final States at sqrt[s]=8??TeV with the Novel CMS Technique of Data Scouting. Phys Rev Lett. 2016 Jul 15; 117(3):031802. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

      • Measurement of [Formula: see text] production with additional jet activity, including [Formula: see text] quark jets, in the dilepton decay channel using pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(7):379. View in: Pubmed

      • Search for heavy resonances decaying to two Higgs bosons in final states containing four b quarks. Eur Phys J C Part Fields. 2016; 76(7):371. View in: Pubmed

      • Measurement of inclusive jet production and nuclear modifications in pPb collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(7):372. View in: Pubmed

      • MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987. View in: Pubmed

      • Autoimmunity and Inflammation in Myelodysplastic Syndromes. Acta Haematol. 2016; 136(2):108-17. View in: Pubmed

      • Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 06 27; 213(7):1285-306. View in: Pubmed

      • GW151226: Observation of Gravitational Waves from a 22-Solar-Mass Binary Black Hole Coalescence. Phys Rev Lett. 2016 Jun 17; 116(24):241103. View in: Pubmed

      • Forward-backward asymmetry of Drell-Yan lepton pairs in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2016; 76(6):325. View in: Pubmed

      • Properties of the Binary Black Hole Merger GW150914. Phys Rev Lett. 2016 Jun 17; 116(24):241102. View in: Pubmed

      • Search for lepton flavour violating decays of heavy resonances and quantum black holes to an [Formula: see text] pair in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76(6):317. View in: Pubmed

      • GW150914: First results from the search for binary black hole coalescence with Advanced LIGO. Phys Rev D. 2016 Jun 15; 93(12). View in: Pubmed

      • Characterization of transient noise in Advanced LIGO relevant to gravitational wave signal GW150914. Class Quantum Gravity. 2016 Jul 07; 33(13). View in: Pubmed

      • Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9. View in: Pubmed

      • Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 May 31; 7(22):32641-51. View in: Pubmed

      • Tests of General Relativity with GW150914. Phys Rev Lett. 2016 Jun 03; 116(22):221101. View in: Pubmed

      • Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia. 2016 10; 30(10):2112-2116. View in: Pubmed

      • KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017 01; 31(1):143-150. View in: Pubmed

      • Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83. View in: Pubmed

      • Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17; 7(20):29131-42. View in: Pubmed

      • Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88. View in: Pubmed

      • Search for massive WH resonances decaying into the [Formula: see text] final state at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2016; 76(5):237. View in: Pubmed

      • Measurement of Long-Range Near-Side Two-Particle Angular Correlations in pp Collisions at sqrt[s]=13??TeV. Phys Rev Lett. 2016 Apr 29; 116(17):172302. View in: Pubmed

      • Transplantation after Remission in Mixed Phenotype Acute Leukemia: A Good Idea. Biol Blood Marrow Transplant. 2016 06; 22(6):971-972. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

      • GW150914: Implications for the Stochastic Gravitational-Wave Background from Binary Black Holes. Phys Rev Lett. 2016 Apr 01; 116(13):131102. View in: Pubmed

      • GW150914: The Advanced LIGO Detectors in the Era of First Discoveries. Phys Rev Lett. 2016 Apr 01; 116(13):131103. View in: Pubmed

      • Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):341-349.e1. View in: Pubmed

      • The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1977-9. View in: Pubmed

      • Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016 Aug; 51(8):1121-6. View in: Pubmed

      • Event generator tunes obtained from underlying event and multiparton scattering measurements. Eur Phys J C Part Fields. 2016; 76:155. View in: Pubmed

      • Measurement of the [Formula: see text] production cross section in the all-jets final state in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2016; 76:128. View in: Pubmed

      • Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett. 2016 May 12; 7(5):476-81. View in: Pubmed

      • Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. Br J Haematol. 2016 06; 173(5):713-21. View in: Pubmed

      • Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306. View in: Pubmed

      • Search for Narrow Resonances Decaying to Dijets in Proton-Proton Collisions at v[s]=13??TeV. Phys Rev Lett. 2016 Feb 19; 116(7):071801. View in: Pubmed

      • Observation of Gravitational Waves from a Binary Black Hole Merger. Phys Rev Lett. 2016 Feb 12; 116(6):061102. View in: Pubmed

      • Prospects for Observing and Localizing Gravitational-Wave Transients with Advanced LIGO and Advanced Virgo. Living Rev Relativ. 2016; 19(1):1. View in: Pubmed

      • Measurement of the Top Quark Pair Production Cross Section in Proton-Proton Collisions at v[s]=13??TeV. Phys Rev Lett. 2016 Feb 05; 116(5):052002. View in: Pubmed

      • Study of B Meson Production in p+Pb Collisions at v[S(NN)]=5.02 TeV Using Exclusive Hadronic Decays. Phys Rev Lett. 2016 Jan 22; 116(3):032301. View in: Pubmed

      • Measurement of differential cross sections for Higgs boson production in the diphoton decay channel in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2016; 76:13. View in: Pubmed

      • Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia. 2016 07; 30(7):1586-9. View in: Pubmed

      • Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb; 91(2):199-204. View in: Pubmed

      • Measurement of the differential cross section for top quark pair production in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(11):542. View in: Pubmed

      • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75. View in: Pubmed

      • Measurements of the [Formula: see text][Formula: see text] production cross sections in the [Formula: see text] channel in proton-proton collisions at [Formula: see text] and [Formula: see text] and combined constraints on triple gauge couplings. Eur Phys J C Part Fields. 2015; 75(10):511. View in: Pubmed

      • Should older adults with AML receive post-remission therapy? Best Pract Res Clin Haematol. 2015 Jun-Sep; 28(2-3):106-11. View in: Pubmed

      • Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206. View in: Pubmed

      • Impact of sleep disturbance in myelodysplastic syndromes (MDS). J Clin Oncol. 2015 Oct 10; 33(29_suppl):99. View in: Pubmed

      • Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015; 4:30. View in: Pubmed

      • Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10; 13:294. View in: Pubmed

      • Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leuk Res. 2015 Sep 09. View in: Pubmed

      • Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015 Oct 29; 373(18):1733-47. View in: Pubmed

      • Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Oct 01; 21(19):4262-9. View in: Pubmed

      • Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016 Jan; 30(1):190-9. View in: Pubmed

      • Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther. 2015 Oct; 14(10):2249-59. View in: Pubmed

      • Constraints on the pMSSM, AMSB model and on other models from the search for long-lived charged particles in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(7):325. View in: Pubmed

      • New Models of Therapy: When Acute Leukemia Becomes Chronic. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1856-7. View in: Pubmed

      • Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan; 30(1):173-81. View in: Pubmed

      • Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41. View in: Pubmed

      • Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia. 2016 Mar; 30(3):754-7. View in: Pubmed

      • CLINICAL PROBLEM-SOLVING. A Man with Fever, Cough, and Rash. N Engl J Med. 2015 Jul 02; 373(1):74-80. View in: Pubmed

      • Distributions of topological observables in inclusive three- and four-jet events in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(7):302. View in: Pubmed

      • Evidence for Collective Multiparticle Correlations in p-Pb Collisions. Phys Rev Lett. 2015 Jul 03; 115(1):012301. View in: Pubmed

      • Constraints on parton distribution functions and extraction of the strong coupling constant from the inclusive jet cross section in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(6):288. View in: Pubmed

      • Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia. 2016 Feb; 30(2):501-4. View in: Pubmed

      • Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015 Jul; 6(4):288-98. View in: Pubmed

      • Search for a standard model Higgs boson produced in association with a top-quark pair and decaying to bottom quarks using a matrix element method. Eur Phys J C Part Fields. 2015; 75(6):251. View in: Pubmed

      • Nuclear effects on the transverse momentum spectra of charged particles in pPb collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(5):237. View in: Pubmed

      • Search for dark matter, extra dimensions, and unparticles in monojet events in proton-proton collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(5):235. View in: Pubmed

      • International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16; 126(3):291-9. View in: Pubmed

      • Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol. 2015 Jul; 28(7):965-76. View in: Pubmed

      • Precise determination of the mass of the Higgs boson and tests of compatibility of its couplings with the standard model predictions using proton collisions at 7 and 8[Formula: see text]. Eur Phys J C Part Fields. 2015; 75(5):212. View in: Pubmed

      • Combined Measurement of the Higgs Boson Mass in pp Collisions at sqrt[s]=7 and 8 TeV with the ATLAS and CMS Experiments. Phys Rev Lett. 2015 May 15; 114(19):191803. View in: Pubmed

      • Measurement of J/? and ?(2S) Prompt Double-Differential Cross Sections in pp Collisions at sqrt[s]=7 TeV. Phys Rev Lett. 2015 May 15; 114(19):191802. View in: Pubmed

      • Measurement of the inclusive 3-jet production differential cross section in proton-proton collisions at 7 TeV and determination of the strong coupling constant in the TeV range. Eur Phys J C Part Fields. 2015; 75(5):186. View in: Pubmed

      • Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8. View in: Pubmed

      • Search for decays of stopped long-lived particles produced in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(4):151. View in: Pubmed

      • Measurements of differential and double-differential Drell-Yan cross sections in proton-proton collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2015; 75(4):147. View in: Pubmed

      • Search for monotop signatures in proton-proton collisions at vs=8??TeV. Phys Rev Lett. 2015 Mar 13; 114(10):101801. View in: Pubmed

      • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7. View in: Pubmed

      • Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):261-72. View in: Pubmed

      • Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1? Curr Opin Hematol. 2015 Mar; 22(2):123-31. View in: Pubmed

      • Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015 Jul; 29(7):1555-1563. View in: Pubmed

      • Search for displaced supersymmetry in events with an electron and a muon with large impact parameters. Phys Rev Lett. 2015 Feb 13; 114(6):061801. View in: Pubmed

      • Measurement of electroweak production of two jets in association with a Z boson in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2015; 75(2):66. View in: Pubmed

      • Study of vector boson scattering and search for new physics in events with two same-sign leptons and two jets. Phys Rev Lett. 2015 Feb 06; 114(5):051801. View in: Pubmed

      • How I treat mixed-phenotype acute leukemia. Blood. 2015 Apr 16; 125(16):2477-85. View in: Pubmed

      • Measurement of prompt ?(2S) to J/? yield ratios in Pb-Pb and p-p collisions at sqrt[sNN]=2.76??TeV. Phys Rev Lett. 2014 Dec 31; 113(26):262301. View in: Pubmed

      • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76. View in: Pubmed

      • Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18679-84. View in: Pubmed

      • Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015 Feb; 39(2):204-10. View in: Pubmed

      • Improved upper limits on the stochastic gravitational-wave background from 2009-2010 LIGO and Virgo data. Phys Rev Lett. 2014 Dec 05; 113(23):231101. View in: Pubmed

      • Search for heavy neutrinos and [Formula: see text] bosons with right-handed couplings in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(11):3149. View in: Pubmed

      • REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805. View in: Pubmed

      • Measurement of differential cross sections for the production of a pair of isolated photons in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(11):3129. View in: Pubmed

      • Observation of the diphoton decay of the Higgs boson and measurement of its properties. Eur Phys J C Part Fields. 2014; 74(10):3076. View in: Pubmed

      • Searches for electroweak production of charginos, neutralinos, and sleptons decaying to leptons and W, Z, and Higgs bosons in pp collisions at 8 TeV. Eur Phys J C Part Fields. 2014; 74(9):3036. View in: Pubmed

      • Evidence of b-jet quenching in PbPb collisions at v(s(NN))=2.76??TeV. Phys Rev Lett. 2014 Sep 26; 113(13):132301. View in: Pubmed

      • Measurement of top quark-antiquark pair production in association with a W or Z boson in pp collisions at [Formula: see text][Formula: see text]. Eur Phys J C Part Fields. 2014; 74(9):3060. View in: Pubmed

      • TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12. View in: Pubmed

      • Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015 Mar; 29(3):567-75. View in: Pubmed

      • Interactive medical case. A man with fever, cough, and rash. N Engl J Med. 2014 Aug 21; 371(8):e11. View in: Pubmed

      • Measurement of jet multiplicity distributions in [Formula: see text] production in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(8):3014. View in: Pubmed

      • Search for invisible decays of Higgs bosons in the vector boson fusion and associated ZH production modes. Eur Phys J C Part Fields. 2014; 74(8):2980. View in: Pubmed

      • AML genomics for the clinician. Semin Hematol. 2014 Oct; 51(4):322-9. View in: Pubmed

      • Measurement of WZ and ZZ production in pp collisions at [Formula: see text] in final states with b-tagged jets. Eur Phys J C Part Fields. 2014; 74(8):2973. View in: Pubmed

      • Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34. View in: Pubmed

      • De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9. View in: Pubmed

      • Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87. View in: Pubmed

      • Search for gravitational waves associated with ?-ray bursts detected by the interplanetary network. Phys Rev Lett. 2014 Jul 04; 113(1):011102. View in: Pubmed

      • High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer. Cancer Res. 2014 Sep 15; 74(18):4983-95. View in: Pubmed

      • Probing color coherence effects in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2014; 74(6):2901. View in: Pubmed

      • Observation of the associated production of a single top quark and a W boson in pp collisions at sqrt[s] = 8 TeV. Phys Rev Lett. 2014 Jun 13; 112(23):231802. View in: Pubmed

      • Study of the production of charged pions, kaons, and protons in pPb collisions at [Formula: see text]5.02[Formula: see text]. Eur Phys J C Part Fields. 2014; 74(6):2847. View in: Pubmed

      • Measurement of inclusive W and Z boson production cross sections in pp collisions at sqrt[s] = 8 TeV. Phys Rev Lett. 2014 May 16; 112(19):191802. View in: Pubmed

      • Measurements of tt spin correlations and top-quark polarization using dilepton final states in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2014 May 09; 112(18):182001. View in: Pubmed

      • Search for flavor-changing neutral currents in top-quark decays t ? Zq in pp collisions at sqrt[s] = 8 TeV. Phys Rev Lett. 2014 May 02; 112(17):171802. View in: Pubmed

      • Search for top-quark partners with charge 5/3 in the same-sign dilepton final state. Phys Rev Lett. 2014 May 02; 112(17):171801. View in: Pubmed

      • Search for top squark and Higgsino production using diphoton Higgs boson decays. Phys Rev Lett. 2014 Apr 25; 112(16):161802. View in: Pubmed

      • Measurement of the top-quark mass in all-jets [Formula: see text] events in pp collisions at [Formula: see text] TeV. Eur Phys J C Part Fields. 2014; 74(4):2758. View in: Pubmed

      • Constraints on cosmic strings from the LIGO-Virgo gravitational-wave detectors. Phys Rev Lett. 2014 Apr 04; 112(13):131101. View in: Pubmed

      • Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia. 2014 Aug; 28(8):1754-1758. View in: Pubmed

      • Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014 Jun 01; 120(11):1670-6. View in: Pubmed

      • NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 May 01; 123(18):2816-25. View in: Pubmed

      • SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10; 25(2):226-42. View in: Pubmed

      • Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther. 2014 May; 13(5):1194-205. View in: Pubmed

      • Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014 Feb 20; 32(6):548-56. View in: Pubmed

      • AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 06; 123(6):905-13. View in: Pubmed

      • Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. View in: Pubmed

      • Jet and underlying event properties as a function of charged-particle multiplicity in proton-proton collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(12):2674. View in: Pubmed

      • GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014 Jun; 28(6):1252-1258. View in: Pubmed

      • A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014 Mar 01; 20(5):1135-45. View in: Pubmed

      • MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42. View in: Pubmed

      • Search for top squarks in R-parity-violating supersymmetry using three or more leptons and b-tagged jets. Phys Rev Lett. 2013 Nov 27; 111(22):221801. View in: Pubmed

      • Searches for new physics using the tt¯ invariant mass distribution in pp collisions at vs=8 TeV. Phys Rev Lett. 2013 Nov 22; 111(21):211804. View in: Pubmed

      • A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4. View in: Pubmed

      • Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013 Dec; 12(12):2651-62. View in: Pubmed

      • Search for supersymmetry in hadronic final states with missing transverse energy using the variables aT and b-quark multiplicity in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(9):2568. View in: Pubmed

      • Measurement of the Bs(0)?µ+ µ- branching fraction and search for B(0)?µ+ µ- with the CMS experiment. Phys Rev Lett. 2013 Sep 06; 111(10):101804. View in: Pubmed

      • Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Curr Cancer Drug Targets. 2013 Sep; 13(7):735-48. View in: Pubmed

      • Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1047-55. View in: Pubmed

      • Inclusive search for supersymmetry using razor variables in pp collisions at vs=7 TeV. Phys Rev Lett. 2013 Aug 23; 111(8):081802. View in: Pubmed

      • MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79. View in: Pubmed

      • Measurement of masses in the [Formula: see text] system by kinematic endpoints in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(7):2494. View in: Pubmed

      • Search for physics beyond the standard model in events with t leptons, jets, and large transverse momentum imbalance in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(7):2493. View in: Pubmed

      • Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013 Jul; 11(7):838-74. View in: Pubmed

      • Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20. View in: Pubmed

      • Search for a standard-model-like Higgs boson with a mass in the range 145 to 1000 GeV at the LHC. Eur Phys J C Part Fields. 2013; 73(6):2469. View in: Pubmed

      • A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013 Oct; 27(10):2023-31. View in: Pubmed

      • Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. J Oncol Pract. 2013 Sep; 9(5):e228-33. View in: Pubmed

      • Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013 Sep; 37(9):998-1003. View in: Pubmed

      • Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117. View in: Pubmed

      • A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20. View in: Pubmed

      • Search for supersymmetry in pp collisions at [Formula: see text] TeV in events with a single lepton, jets, and missing transverse momentum. Eur Phys J C Part Fields. 2013; 73(5):2404. View in: Pubmed

      • Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013 Jun 10; 31(17):2086-93. View in: Pubmed

      • Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2013 Jul; 37(7):747-51. View in: Pubmed

      • Consolidation chemotherapy for adults with AML in first remission: is there a best choice? J Clin Oncol. 2013 Jun 10; 31(17):2067-9. View in: Pubmed

      • Measurement of associated production of vector bosons and top quark-antiquark pairs in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2013 Apr 26; 110(17):172002. View in: Pubmed

      • Search for pair-produced dijet resonances in four-jet final states in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2013 Apr 05; 110(14):141802. View in: Pubmed

      • Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology. Expert Rev Hematol. 2013 Apr; 6(2):127-9. View in: Pubmed

      • SYK regulates mTOR signaling in AML. Leukemia. 2013 Nov; 27(11):2118-28. View in: Pubmed

      • Acute myeloid leukemia in first remission: to choose transplantation or not? J Clin Oncol. 2013 Apr 01; 31(10):1262-6. View in: Pubmed

      • Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473. View in: Pubmed

      • Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett. 2013 Feb 22; 110(8):081803. View in: Pubmed

      • Search for pair production of third-generation leptoquarks and top squarks in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2013 Feb 22; 110(8):081801. View in: Pubmed

      • Measurement of the ?1S, ?2S, and ?3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2013 Feb 22; 110(8):081802. View in: Pubmed

      • Measurement of the sum of WW and WZ production with W+dijet events in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2013; 73(2):2283. View in: Pubmed

      • KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr; 161(1):117-27. View in: Pubmed

      • Measurement of the azimuthal anisotropy of neutral pions in Pb-Pb collisions at sqrt[s](NN)] = 2.76 TeV. Phys Rev Lett. 2013 Jan 25; 110(4):042301. View in: Pubmed

      • Evidence for associated production of a single top quark and W boson in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2013 Jan 11; 110(2):022003. View in: Pubmed

      • Search for heavy neutrinos and W(R) bosons with right-handed couplings in a left-right symmetric model in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2012 Dec 28; 109(26):261802. View in: Pubmed

      • Study of the Dijet mass spectrum in pp ? W+jets events at sqrt[s] = 7 TeV. Phys Rev Lett. 2012 Dec 21; 109(25):251801. View in: Pubmed

      • Measurement of the relative prompt production rate of ?c2 and ?c1 in pp collisions at [Formula: see text]. Eur Phys J C Part Fields. 2012; 72(12):2251. View in: Pubmed

      • Observation of sequential ? suppression in PbPb collisions. Phys Rev Lett. 2012 Nov 30; 109(22):222301. View in: Pubmed

      • Is it time to revisit standard post-remission therapy? Best Pract Res Clin Haematol. 2012 Dec; 25(4):437-41. View in: Pubmed

      • Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9. View in: Pubmed

      • Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at vs = 7 TeV. Phys Rev Lett. 2012 Oct 26; 109(17):171803. View in: Pubmed

      • Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012 Nov 29; 120(23):4649-52. View in: Pubmed

      • Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012 Oct 12; 151(2):344-55. View in: Pubmed

      • Measurement of the pseudorapidity and centrality dependence of the transverse energy density in Pb-Pb collisions at v(s(NN))=2.76 TeV. Phys Rev Lett. 2012 Oct 12; 109(15):152303. View in: Pubmed

      • Search for a W' or techni-? decaying into WZ in pp Collisions at sqrt[s] = 7??TeV. Phys Rev Lett. 2012 Oct 05; 109(14):141801. View in: Pubmed

      • Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103. View in: Pubmed

      • Search for a light pseudoscalar Higgs boson in the dimuon decay channel in pp collisions at vs = 7 TeV. Phys Rev Lett. 2012 Sep 21; 109(12):121801. View in: Pubmed

      • Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012 Dec 20; 30(36):4515-23. View in: Pubmed

      • Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2012 Sep 14; 109(11):111806. View in: Pubmed

      • Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012 Oct 15; 18(20):5761-72. View in: Pubmed

      • Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett. 2012 Aug 17; 109(7):071803. View in: Pubmed

      • NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw. 2012 Aug; 10(8):984-1021. View in: Pubmed

      • Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76??TeV. Phys Rev Lett. 2012 Jul 13; 109(2):022301. View in: Pubmed

      • The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11. View in: Pubmed

      • Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8. View in: Pubmed

      • Search for dark matter and large extra dimensions in pp collisions yielding a photon and missing transverse energy. Phys Rev Lett. 2012 Jun 29; 108(26):261803. View in: Pubmed

      • Observation of a new ?b baryon. Phys Rev Lett. 2012 Jun 22; 108(25):252002. View in: Pubmed

      • Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8. View in: Pubmed

      • Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44. View in: Pubmed

      • Search for the standard model Higgs boson in the decay channel H?ZZ?4l in pp collisions at vs=7 TeV. Phys Rev Lett. 2012 Mar 16; 108(11):111804. View in: Pubmed

      • Search for signatures of extra dimensions in the diphoton mass spectrum at the large hadron collider. Phys Rev Lett. 2012 Mar 16; 108(11):111801. View in: Pubmed

      • The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47. View in: Pubmed

      • Directional limits on persistent gravitational waves using LIGO S5 science data. Phys Rev Lett. 2011 Dec 30; 107(27):271102. View in: Pubmed

      • Search for a vectorlike quark with charge 2/3 in t+Z events from pp collisions at vs=7 TeV. Phys Rev Lett. 2011 Dec 30; 107(27):271802. View in: Pubmed

      • AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD. Leuk Res. 2012 Feb; 36(2):205-11. View in: Pubmed

      • Treatment of elderly acute myeloid leukemia patients. Curr Treat Options Oncol. 2011 Dec; 12(4):341-53. View in: Pubmed

      • Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett. 2011 Nov 25; 107(22):221804. View in: Pubmed

      • Search for new physics with a monojet and missing transverse energy in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 Nov 11; 107(20):201804. View in: Pubmed

      • Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML? Best Pract Res Clin Haematol. 2011 Dec; 24(4):509-14. View in: Pubmed

      • Search for B(s)(0) ? µ+ µ- and B(0) ? µ+ µ- decays in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2011 Nov 04; 107(19):191802. View in: Pubmed

      • Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33. View in: Pubmed

      • Measurement of the inclusive jet cross section in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 Sep 23; 107(13):132001. View in: Pubmed

      • Search for three-jet resonances in pp collisions at square root(s)=7??TeV. Phys Rev Lett. 2011 Sep 02; 107(10):101801. View in: Pubmed

      • Measurement of the t-channel single top quark production cross section in pp collisions at vs=7??TeV. Phys Rev Lett. 2011 Aug 26; 107(9):091802. View in: Pubmed

      • Image defocus and altered retinal gene expression in chick: clues to the pathogenesis of ametropia. Invest Ophthalmol Vis Sci. 2011 Jul 29; 52(8):5765-77. View in: Pubmed

      • Indications of suppression of excited ? states in Pb-Pb collisions at v(s(NN))=2.76 TeV. Phys Rev Lett. 2011 Jul 29; 107(5):052302. View in: Pubmed

      • Lenalidomide in AML: del(5q) or who? Blood. 2011 Jul 21; 118(3):481-2. View in: Pubmed

      • Measurement of the polarization of W bosons with large transverse momenta in W + jets events at the LHC. Phys Rev Lett. 2011 Jul 08; 107(2):021802. View in: Pubmed

      • Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7. View in: Pubmed

      • Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011 Dec; 35(12):1611-5. View in: Pubmed

      • Measurement of the B0 production cross section in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett. 2011 Jun 24; 106(25):252001. View in: Pubmed

      • Search for neutral minimal supersymmetric standard model Higgs bosons decaying to tau pairs in pp collisions at vs=7 TeV. Phys Rev Lett. 2011 Jun 10; 106(23):231801. View in: Pubmed

      • Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood. 2011 Jul 28; 118(4):903-15. View in: Pubmed

      • Search for supersymmetry in pp collisions at v7 TeV in events with two photons and missing transverse energy. Phys Rev Lett. 2011 May 27; 106(21):211802. View in: Pubmed

      • Study of Z Boson Production in PbPb Collisions at vS(NN)=2.76 TeV. Phys Rev Lett. 2011 May 27; 106(21):212301. View in: Pubmed

      • A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). J Clin Oncol. 2011 May 20; 29(15_suppl):6520. View in: Pubmed

      • Vaginal bleeding in women with leukemia. J Clin Oncol. 2011 May 20; 29(15_suppl):6577. View in: Pubmed

      • CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS199. View in: Pubmed

      • Measurement of dijet angular distributions and search for quark compositeness in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 May 20; 106(20):201804. View in: Pubmed

      • Search for pair production of second-generation scalar leptoquarks in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 May 20; 106(20):201803. View in: Pubmed

      • Search for pair production of first-generation scalar leptoquarks in pp collisions at vs = 7 TeV. Phys Rev Lett. 2011 May 20; 106(20):201802. View in: Pubmed

      • Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011; 16(6):904-11. View in: Pubmed

      • Dijet azimuthal decorrelations in pp collisions at vs=7 TeV. Phys Rev Lett. 2011 Mar 25; 106(12):122003. View in: Pubmed

      • MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70. View in: Pubmed

      • Measurement of the B(+) production cross section in pp collisions at sqrt[s]=7??TeV. Phys Rev Lett. 2011 Mar 18; 106(11):112001. View in: Pubmed

      • Acute myeloid leukemia. J Natl Compr Canc Netw. 2011 Mar; 9(3):280-317. View in: Pubmed

      • Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011 Apr 01; 29(10):1290-6. View in: Pubmed

      • Measurement of the isolated prompt photon production cross section in pp collisions at vs=7??TeV. Phys Rev Lett. 2011 Feb 25; 106(8):082001. View in: Pubmed

      • Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011 May; 25(5):800-7. View in: Pubmed

      • Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations. Cancer Genet. 2011 Feb; 204(2):68-76. View in: Pubmed

      • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301. View in: Pubmed

      • Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 01; 29(7):789-96. View in: Pubmed

      • Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett. 2011 Jan 07; 106(1):011801. View in: Pubmed

      • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan; 9(1):30-56. View in: Pubmed

      • Search for quark compositeness with the dijet centrality ratio in pp collisions at vs=7 TeV. Phys Rev Lett. 2010 Dec 31; 105(26):262001. View in: Pubmed

      • Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010 Dec; 85(12):956-7. View in: Pubmed

      • Search for dijet resonances in 7 TeV pp collisions at CMS. Phys Rev Lett. 2010 Nov 19; 105(21):211801. View in: Pubmed

      • New agents in post-remission therapy. Best Pract Res Clin Haematol. 2010 Dec; 23(4):475-9. View in: Pubmed

      • Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010 Dec; 24(12):2100-9. View in: Pubmed

      • Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010 Sep 01; 10(5):483-91. View in: Pubmed

      • Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther. 2010 Sep; 9(9):2468-77. View in: Pubmed

      • Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 01; 28(28):4339-45. View in: Pubmed

      • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7. View in: Pubmed

      • High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33. View in: Pubmed

      • FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Nov 04; 116(18):3622-6. View in: Pubmed

      • First measurement of Bose-Einstein correlations in proton-proton collisions at vs=0.9 and 2.36 TeV at the LHC. Phys Rev Lett. 2010 Jul 16; 105(3):032001. View in: Pubmed

      • Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett. 2010 Jul 09; 105(2):022002. View in: Pubmed

      • Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res. 2010 Jul; 8(7):986-93. View in: Pubmed

      • CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):e409-11. View in: Pubmed

      • Utility of digital stereo images for optic disc evaluation. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5667-74. View in: Pubmed

      • The role of molecular tests in acute myelogenous leukemia treatment decisions. Curr Hematol Malig Rep. 2010 Apr; 5(2):109-17. View in: Pubmed

      • Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):389-406. View in: Pubmed

      • Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. Leuk Res. 2010 Jul; 34(7):939-41. View in: Pubmed

      • Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66. View in: Pubmed

      • NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2009 Dec 29; 7 Suppl 9:S1-16. View in: Pubmed

      • Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7. View in: Pubmed

      • Prognostic factors in AML in relation to (ab)normal karyotype. Best Pract Res Clin Haematol. 2009 Dec; 22(4):523-8. View in: Pubmed

      • Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94. View in: Pubmed

      • Screens, iron, and leukemia. Blood. 2009 Oct 01; 114(14):2857-8. View in: Pubmed

      • Langerhans cell histiocytosis following acute leukemia in an adult. Am J Hematol. 2009 Oct; 84(10):693-4. View in: Pubmed

      • Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression. Mol Cell Biol. 2009 Nov; 29(21):5911-22. View in: Pubmed

      • An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature. 2009 Aug 20; 460(7258):990-4. View in: Pubmed

      • Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol. 2009 Aug; 7(8):1-14; quiz 2 p following 14. View in: Pubmed

      • Iron chelation therapy in myelodysplastic syndrome - Cui bono? Leukemia. 2009 Aug; 23(8):1373. View in: Pubmed

      • Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45. View in: Pubmed

      • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61. View in: Pubmed

      • Management of related donor care: a European survey. Bone Marrow Transplant. 2010 Jan; 45(1):97-101. View in: Pubmed

      • Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9. View in: Pubmed

      • A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol. 2009 May 20; 27(15_suppl):7048. View in: Pubmed

      • Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS). J Clin Oncol. 2009 May 20; 27(15_suppl):7007. View in: Pubmed

      • FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun; 12(3):81-9. View in: Pubmed

      • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7. View in: Pubmed

      • How I treat patients with myelodysplastic syndromes. Blood. 2009 Jun 18; 113(25):6296-303. View in: Pubmed

      • Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11; 113(24):6193-205. View in: Pubmed

      • A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9. View in: Pubmed

      • The role of myeloid growth factors in acute leukemia. J Natl Compr Canc Netw. 2009 Jan; 7(1):84-91. View in: Pubmed

      • Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93. View in: Pubmed

      • Are new agents really making a difference in MDS? Best Pract Res Clin Haematol. 2008 Dec; 21(4):639-46. View in: Pubmed

      • Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):1-15. View in: Pubmed

      • FLT3 inhibitors in acute myeloid leukemia. Expert Rev Hematol. 2008 Dec; 1(2):153-60. View in: Pubmed

      • Search for gravitational-wave bursts from soft gamma repeaters. Phys Rev Lett. 2008 Nov 21; 101(21):211102. View in: Pubmed

      • Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8. View in: Pubmed

      • Timed sequential induction chemotherapy in AML: time for reflection. Am J Hematol. 2008 Nov; 83(11):829-30. View in: Pubmed

      • Acute myeloid leukemia. J Natl Compr Canc Netw. 2008 Nov; 6(10):962-93. View in: Pubmed

      • Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7. View in: Pubmed

      • Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct; 6(9):902-26. View in: Pubmed

      • Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15; 112(13):5161-70. View in: Pubmed

      • The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant. 2009 Jan; 43(2):141-7. View in: Pubmed

      • In vivo human choroidal thickness measurements: evidence for diurnal fluctuations. Invest Ophthalmol Vis Sci. 2009 Jan; 50(1):5-12. View in: Pubmed

      • Elevated serum ferritin in patients with a myelodysplastic syndrome: how much of a problem? Am J Hematol. 2008 Aug; 83(8):609-10. View in: Pubmed

      • A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64. View in: Pubmed

      • Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8. View in: Pubmed

      • New agents for the treatment of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2008 Jul; 3(3):135-43. View in: Pubmed

      • Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81. View in: Pubmed

      • Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Oct 20; 26(30):4934-9. View in: Pubmed

      • Classification of myelodysplastic syndrome in a national registry of recently-diagnosed patients-the Patient Registries at Slone: MDS. J Clin Oncol. 2008 May 20; 26(15_suppl):6628. View in: Pubmed

      • Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. J Clin Oncol. 2008 May 20; 26(15_suppl):7015. View in: Pubmed

      • Pharmacokinetics (PK) and pharmacodynamics (PD) of midostaurin (PKC412) in patients with acute myeloid leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7064. View in: Pubmed

      • Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008 May 20; 26(15_suppl):7009. View in: Pubmed

      • Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008 May; 7(5):1121-9. View in: Pubmed

      • Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6. View in: Pubmed

      • Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54. View in: Pubmed

      • High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 01; 111(9):4788-96. View in: Pubmed

      • The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2008 Feb; 14(2):137-80. View in: Pubmed

      • An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008 Feb; 5(2):e35. View in: Pubmed

      • Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood. 2008 Apr 01; 111(7):3723-34. View in: Pubmed

      • Lenalidomide in myelodysplastic syndromes: where do we go from here? Curr Hematol Malig Rep. 2008 Jan; 3(1):5-9. View in: Pubmed

      • A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008 Mar 01; 111(5):2589-96. View in: Pubmed

      • MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007 Dec 15; 67(24):11576-84. View in: Pubmed

      • Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007 Dec; 12(6):501-13. View in: Pubmed

      • Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008 Feb 01; 111(3):1039-43. View in: Pubmed

      • The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007 Oct 01; 110(7):1509-19. View in: Pubmed

      • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 01; 111(1):86-93. View in: Pubmed

      • Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82. View in: Pubmed

      • Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2007 Apr 01; 13(7):2254-60. View in: Pubmed

      • Novel therapeutic agents in acute myeloid leukemia. Exp Hematol. 2007 Apr; 35(4 Suppl 1):163-6. View in: Pubmed

      • Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64. View in: Pubmed

      • A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007 Jun 15; 109(12):5151-6. View in: Pubmed

      • Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15; 109(12):5136-42. View in: Pubmed

      • Torsades de pointes associated with voriconazole use. Transpl Infect Dis. 2007 Mar; 9(1):33-6. View in: Pubmed

      • Targeted agents in AML: much more to do. Best Pract Res Clin Haematol. 2007 Mar; 20(1):39-48. View in: Pubmed

      • Azacitidine: A new agent in myelodysplastic syndromes. Cancer Investigation. 2007; In Press. View in: Pubmed

      • Torsades DE Pointes Associated with Voriconazole Use. Tranplant Infectious Disease. 2007; 9:33-36. View in: Pubmed

      • Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007 Jan; 13(1):78-83. View in: Pubmed

      • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 07; 355(23):2408-17. View in: Pubmed

      • Novel Therapies in Leukemia. 2006. View in: Pubmed

      • What's new in the treatment of lymphoma. 2006. View in: Pubmed

      • Acute myeloid leukemia clinical practice guidelines in oncology. 2006. View in: Pubmed

      • Improving treatment outcomes for patients with hematologic malignancies. Novel treatment and erythropoietic agents: A report from ASCO 2006. 2006. View in: Pubmed

      • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15; 109(6):2303-9. View in: Pubmed

      • End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6. View in: Pubmed

      • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 05; 355(14):1456-65. View in: Pubmed

      • Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55. View in: Pubmed

      • Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia. 2006 Nov; 20(11):1963-6. View in: Pubmed

      • Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 01; 108(12):3674-81. View in: Pubmed

      • Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15; 108(10):3477-83. View in: Pubmed

      • Quality of life intervention for men with biochemical recurrence of prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):18585. View in: Pubmed

      • Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6576. View in: Pubmed

      • A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6585. View in: Pubmed

      • Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3556s-63s. View in: Pubmed

      • Myelodysplastic syndromes clinical practice guideliens in oncology. 2006. View in: Pubmed

      • Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes? J Clin Oncol. 2006 Jun 01; 24(16):2414-6. View in: Pubmed

      • Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May; 28(5):1099-103. View in: Pubmed

      • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15; 108(2):419-25. View in: Pubmed

      • Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73. View in: Pubmed

      • Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan; 4(1):58-77. View in: Pubmed

      • Preliminary results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. Blood. 2006; 108:171a. View in: Pubmed

      • A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Onc. 2006; 24:357s. View in: Pubmed

      • Six year followup results of a phase II study of imatinib in late chronic refractoriness/intolerance. Blood. 2006; 108:130a. View in: Pubmed

      • Impact of cytogenetics and prior therapy on outcome of AML and MDS after allogeneic transplantation. Blood. 2006; 108:80a. View in: Pubmed

      • A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL)and other leukemias. J Clin Onc. 2006; 24:357s. View in: Pubmed

      • Preliminary results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. Blood. 2006; 108:171a. View in: Pubmed

      • Treatment for Acute Myeloid Leukemia in Patients Under Age 60. Clinical Malignant Hematology. 2006; 41-50. View in: Pubmed

      • An erythroid differentiation gene expression signature predicts response to lenalidomide in myelodysplasia. Blood. 2006; 108:754a. View in: Pubmed

      • FLT3 Inhibitors. Annals of Hematology. 2006; 85:Supplement 1. View in: Pubmed

      • Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan; 4(1):16-36. View in: Pubmed

      • Phase IB study of PKC412, an oral FLT3 kinase inhibitor in sequential and simultaneouos combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (patients) with acute myeloid leukemia (AML) under age 61. Blood. 2006; 108:51a. View in: Pubmed

      • Monitoring imatinib resistance with a "polony" assay: Towards tailored therapy of chronic myelogenous leukemias (CML). Blood. 2006; 108:251a. View in: Pubmed

      • Phase I/II Study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood. 2006; 108:51a. View in: Pubmed

      • Phase IB study of PKC412, an oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicni and Cytarabine (DA) Induction and High Dose cytarabine consolidation in newly diagnosed adult patients with acute myeloid leukemia (AML under age 61). Blood. 2006; 108:51a. View in: Pubmed

      • Acute Myeloid Leukemia in Adults Mast Cell Leukemia and Other Mast Cell Neoplasms. Cancer Medicine. 2006; 1739-1760. View in: Pubmed

      • Monitoring imatinib resistance with a "polony" assay: towards tailored therapy of chronic myelogenous leukemia (CML). Blood. 2006; 108:251a. View in: Pubmed

      • Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients less than 60 years in first complete remission (CALGB 9720). Blood. 2006; 108:129a. View in: Pubmed

      • Oncology: An Evidence-Based Approach. 2006. View in: Pubmed

      • A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood. 2006; 108:526a.. View in: Pubmed

      • Phase III study of immunotherapy with recombinant interleukin-2(IL-2) versus no further therapy in acute myeloid leukemia (AML) patients less than or equal to 60 years in first complete remission (CALGB 9720). Blood. 2006; 108:129a. View in: Pubmed

      • Impact of cytogenetics and prior therapy on outcome of AML and MDS after allogeneic transplantation. Blood. 2006; 108:80a. View in: Pubmed

      • Six year follow-up results of a phase II study of imatinib in late chronic refractoriness/intolerance. Blood. 2006; 108:130a. View in: Pubmed

      • Emil is required for normal cell cycle progression in zebrafish myelopoiesis and likely functions as a haploinsufficient tumor suppresor on chromosome 6q in human leukemias. Blood. 2006; 526a. View in: Pubmed

      • An erythroid differentiation gene expression signature predicts response to lenalidomide in myelodysplasia. Blood. 2006; 108:754a. View in: Pubmed

      • Emil is required for normal cell cycle progression in zebrafish myelopoiesis and likely function as a haploinsufficient tumor suppressor on chromosome 6q in human leukemias. Blood. 2006; 108:409a. View in: Pubmed

      • Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML). Blood. 2006; 108:51a. View in: Pubmed

      • Older AML patients: fit for what?. Blood. 2006; 108:3232-3233. View in: Pubmed

      • Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine. J Clin Onc. 2006; 24:355s. View in: Pubmed

      • Targeted Therapy in AML. 2005. View in: Pubmed

      • Update on targeted therapy in acute myeloid leukemia. 2005. View in: Pubmed

      • Acute lymphoblastic leukemia: Time for T. 2005. View in: Pubmed

      • Progress in acute lymphoblastic leukemia and acute promyelocytic leukemia. 2005. View in: Pubmed

      • Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006 Jan 01; 107(1):293-300. View in: Pubmed

      • The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 2005 Aug 15; 65(16):7338-47. View in: Pubmed

      • Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4110-6. View in: Pubmed

      • Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005 Jun; 23(16_suppl):2527. View in: Pubmed

      • Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. Clin Adv Hematol Oncol. 2005 May; 3(5):391-7, 429. View in: Pubmed

      • New Treatment Options for the Elderly AML Patient. 2005. View in: Pubmed

      • New Advances for Managing Stomatitis in Chemotherapy and Bone Marrow Transplant Patients. 2005. View in: Pubmed

      • Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005 Jul 15; 106(2):721-4. View in: Pubmed

      • Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94. View in: Pubmed

      • MDS: practical treatment approaches for physicians and nurses. Clin Adv Hematol Oncol. 2005 Feb; 3(2):1-7. View in: Pubmed

      • The Lance/Karp Article Reviewed. Oncology. 2005; 19:1049-1050. View in: Pubmed

      • Pharmacokinetic and pharmacodynamic studies of lestaurtinib (CEP-701) and PKC412: cytotoxicity is often dependent on non-FLT3 mediated effects. Blood. 2005; 106:692a. View in: Pubmed

      • Leukemia derived dendritic cells (LDCs) are functionally deficient and inferior to DC/Leukemia Fusion Cells as a tumor vaccine for AML. Blood. 2005; 106:782a. View in: Pubmed

      • Phase IB study of PKC412, an oral FLT3 kinase inhibito in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood. 2005; 106:121a. View in: Pubmed

      • Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): Final results from Cancer and Leukemia Group B study 19802. Blood. 2005; 106:521a. View in: Pubmed

      • KIAA 1509 is a novel PDGRFB fusion primer in imatinib-responsive myeloproliferative disease associate with a t95;14)(q33;q32). Leukemia. 2005; 19:27-30. View in: Pubmed

      • Phase III randomized multicenter study of humanized anti-CD33 monoclonal antibody, lintuzumab, in combinatino with chemotherapy. J Clin Oncol. 2005; 23:4110-16. View in: Pubmed

      • Overview of the treatment of myelodysplastic syndromes. Clinical advances in hematology and oncology. 2005; 13:2-5. View in: Pubmed

      • Five Year followup results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory/intolerant of interferon-alpha. Blood. 2005; 106:317a. View in: Pubmed

      • Response rates in patients with acute myeloid leukemia (AML), treated with azacitidine, using WHO and International Working Group (IWG) criteria for myelodysplastic syndrome (MDS). Blood. 2005; 106:525a. View in: Pubmed

      • Myelodysplastic syndromes: biology and management. Hematology: Basic principles and practice. 2005; 1195-1208. View in: Pubmed

      • Metastatic cancer of unknown primary site. Harrison's Principles of Internal Medicine. 2005; 562-565. View in: Pubmed

      • Addition of bortezomib (Velcade) to AML induction chemotehrapy is well tolerated and results in a high complete remission rate. Blood. 2005; 106:780a. View in: Pubmed

      • KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005 Jan; 19(1):27-30. View in: Pubmed

      • Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004 Dec; 28(12):1303-12. View in: Pubmed

      • Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93. View in: Pubmed

      • Chronic myeloid leukemia and the application of rational drug design. Virtual Mentor. 2004 Nov 01; 6(11). View in: Pubmed

      • Treatment options for myelodysplastic syndromes. Cancer Control. 2004 Nov-Dec; 11(6 Suppl):7-10. View in: Pubmed

      • Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4. View in: Pubmed

      • PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14479-84. View in: Pubmed

      • After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005 Jan 01; 105(1):22-30. View in: Pubmed

      • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 01; 105(1):54-60. View in: Pubmed

      • Acute Myeloid Leukemia: NCCN Practice Guidelines. 2004. View in: Pubmed

      • Myelodysplastic Syndromes. NCCN Practice Guidelines. 2004. View in: Pubmed

      • Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71. View in: Pubmed

      • A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3024. View in: Pubmed

      • Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8. View in: Pubmed

      • Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004 Apr; 18(4):809-16. View in: Pubmed

      • Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Semin Oncol. 2004 Apr; 31(2 Suppl 6):12-7. View in: Pubmed

      • Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology. 2004 Mar 09; 62(5):719-25. View in: Pubmed

      • Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42. View in: Pubmed

      • Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004; 98-117. View in: Pubmed

      • A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 199902. Blood. 2004; 104:249a. View in: Pubmed

      • Treatment Options for Myelodysplastic Syndromes. Cancer Control (Supplement). 2004; 11:7-10. View in: Pubmed

      • FLT3 Target practice. Blood. 2004; 104:915-916. View in: Pubmed

      • Trnasplantation Predictive of Overall and Progression Free Survival but not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS. Blood. 2004; 104:57a. View in: Pubmed

      • Novel Therapies in AML: Order out of Plethora. Leukemia 2004: Towards the Cure, third international meeting of the global organization against leukemia. 2004. View in: Pubmed

      • Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood. 2004; 104:496a. View in: Pubmed

      • Phase I study of PKC412 an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with daunorubicin and cytarabine (DAA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML. Blood. 2004; 104:78a. View in: Pubmed

      • Phase I dose escalating trial of bortezomib (Velcade) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia. Blood. 2004; 104:498a. View in: Pubmed

      • Safety profile of Zarnestra (tipifarnib) in patienits with relapsed and refractory acute myeloid leukemia (AML). The Hematology Journal. 2004; 5(S2):S34. View in: Pubmed

      • Identification of molecular predictors of response to Zarnestra (tipifarnib R115777) in relapsed and refractory acute myeloid leukemia. Blood. 2004; 104:246a. View in: Pubmed

      • PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004; 83 Suppl 1:S89-90. View in: Pubmed

      • Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist. 2004; 9(3):259-70. View in: Pubmed

      • Acute lymphoblastic leukemia: encouraged by profiles. 2003. View in: Pubmed

      • Acute lymphoblastic leukemia: new genes and nascent novel combinations. 2003. View in: Pubmed

      • Myopia and natural lighting extremes: risk factors in Finnish army conscripts. Acta Ophthalmol Scand. 2003 Dec; 81(6):588-95. View in: Pubmed

      • Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003 Nov 01; 102(9):3455-6. View in: Pubmed

      • Leukemia in Older Patients. 2003. View in: Pubmed

      • Highly precise eye length measurements in children aged 3 through 12 years. Arch Ophthalmol. 2003 Jul; 121(7):985-90. View in: Pubmed

      • Acute and chronic leukemias: time to exploit the targets. 2003. View in: Pubmed

      • Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82. View in: Pubmed

      • PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69. View in: Pubmed

      • A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14. View in: Pubmed

      • Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003 Mar 15; 97(6):1471-80. View in: Pubmed

      • Induction and postremission therapy: new agents. Leukemia. 2003 Mar; 17(3):496-8. View in: Pubmed

      • Cancer of unknown primary. Clinical Hematology and Oncology. 2003; 313-317. View in: Pubmed

      • Inhibition of FLT3 tyrosine kinase: an evolving therapeutic strategy in acute myeloid leukemia. 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy. 2003; 22. View in: Pubmed

      • Mast cell leukemia and other mast cell neoplasms. Cancer Medicine. 2003; 2157-2161. View in: Pubmed

      • Induction and postremission therapy: new agents. Leuk. 2003; 17:496-8. View in: Pubmed

      • Acute myeloid leukemia in adults. Cancer Medicine. 2003; 2095-2115. View in: Pubmed

      • Successful treatment of angioinvasive aspergillosis during prolonged neutropenina wiht lipsomal amphotericin, voriconazole, and caspofungin. Infect Dis in Clin Prac. 2003; 11:355-8. View in: Pubmed

      • Commentary on DNA methylation in MDS and AML. Highlights from the 45th Annual Meeting of the American Society of Hematology. 2003; not available. View in: Pubmed

      • FLT-3 tyrosine kinase (TK) inhibition: an emerging therapy in acute myeloid leukemia (AML). Chemotherapy Foundation Symposium XXI: Innovative Cancer Therapy for Tomorrow. 2003; 20-21. View in: Pubmed

      • Pathology and morphology of chronic leukemias and related disorders. Neoplastic Diseases of the Blood. 2003. View in: Pubmed

      • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994-1004. View in: Pubmed

      • Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9. View in: Pubmed

      • Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51. View in: Pubmed

      • The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002 Nov-Dec; 52(6):363-71. View in: Pubmed

      • Older adults with acute myeloid leukemia. Curr Oncol Rep. 2002 Sep; 4(5):403-9. View in: Pubmed

      • New therapies in leukemia: renewed hope. J Hematother Stem Cell Res. 2002 Aug; 11(4):583-7. View in: Pubmed

      • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36. View in: Pubmed

      • Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol. 2002 Jul; 39(3 Suppl 2):4-10. View in: Pubmed

      • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15; 20(10):2429-40. View in: Pubmed

      • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9. View in: Pubmed

      • Darkness and near work: myopia and its progression in third-year law students. Ophthalmology. 2002 May; 109(5):1032-8. View in: Pubmed

      • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Mar 15; 99(6):1928-37. View in: Pubmed

      • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28; 346(9):645-52. View in: Pubmed

      • A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult Scler. 2002 Feb; 8(1):24-9. View in: Pubmed

      • Highlights of leukemia research: Introduction. J Clin Oncol. 2002; 7:197-201. View in: Pubmed

      • Leukemia in Older Adults. Practice Guidelines in Oncology (NCCN AML Guidelines). 2002. View in: Pubmed

      • Acute Leukemias. Intensive Care Medicine. 2002; 1295-1302. View in: Pubmed

      • Gemtuzumab ozogamicin given in combination with cytarabine and daunorubicini n patients less than 60 years old with untreated acute myeloid leukemia. Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow. 2002. View in: Pubmed

      • Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7. View in: Pubmed

      • The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol. 2002 Jan; 14(1):24-30. View in: Pubmed

      • United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15; 19(18):3852-60. View in: Pubmed

      • Myelodysplastic syndromes standardized response criteria: further definition. Blood. 2001 Sep 15; 98(6):1985. View in: Pubmed

      • Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001 Aug 01; 98(3):548-53. View in: Pubmed

      • Postremission therapy in adults with acute myeloid leukemia. Semin Hematol. 2001 Jul; 38(3 Suppl 6):17-23. View in: Pubmed

      • High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001 Jun 01; 97(11):3574-80. View in: Pubmed

      • Measurement of CP-violating asymmetries in B0 decays to CP eigenstates. Phys Rev Lett. 2001 Mar 19; 86(12):2515-22. View in: Pubmed

      • CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9. View in: Pubmed

      • Elliptic flow in Au+Au collisions at square root(S)NN = 130 GeV. Phys Rev Lett. 2001 Jan 15; 86(3):402-7. View in: Pubmed

      • Metastatic cancer of unknown primary site. Harrison's Principles of Internal Medicine. 2001; 628-632. View in: Pubmed

      • Therapy of older adults with AML: CALGB studies. Acute Leukemias VIII: Prognostic factors and treatment strategies. 2001; 631-638. View in: Pubmed

      • Harrison's Principles of Internal Medicine. 2001. View in: Pubmed

      • Hematological-oncological disorders and cardiovascular disease. Heart Disease. 2001; 2223-2243. View in: Pubmed

      • Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 01; 96(12):3671-4. View in: Pubmed

      • NCCN Practice Guidelines for Acute Myelogenous Leukemia. Oncology (Williston Park). 2000 Nov; 14(11A):53-61. View in: Pubmed

      • NCCN Practic Guidelines for Acute Myelogenous Leukemia. 2000. View in: Pubmed

      • A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5. View in: Pubmed

      • Acute myeloid leukemia in adults. Clinical Oncology. 2000; 2490-2510. View in: Pubmed

      • Acute myeloid leukemia in adults. Cancer Medicine. 2000; 1947-70. View in: Pubmed

      • Myelodysplastic syndromes. Molecular Hematology. 2000; 75-84. View in: Pubmed

      • Mast cell leukemia and other mast cell neoplasms. Cancer Medicine. 2000; 2086-89. View in: Pubmed

      • Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35. View in: Pubmed

      • Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999; 340:764-71. View in: Pubmed

      • Astrocyte nitric oxide causes neuronal mitochondrial damage, but antioxidant release limits neuronal cell death. Ann N Y Acad Sci. 1999; 893:400-3. View in: Pubmed

      • Functional role for protein kinase Cbeta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells. Mol Cell Biol. 1999 Jan; 19(1):461-70. View in: Pubmed

      • Leukemia in the Elderly. American Society of Hematology Education Program Book. 1999; 510-6. View in: Pubmed

      • Interstitial pneumonitis following mitozantrone, chlorambucil and prednisolone (MCP) chemotherapy. Clin Oncol (R Coll Radiol). 1999; 11(3):184-6. View in: Pubmed

      • First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Alzheimer Dis Assoc Disord. 1998 Dec; 12(4):266-80. View in: Pubmed

      • Blood product requirements in patients undergoing elective endovascular abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 1998 Nov; 16(5):390-4. View in: Pubmed

      • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998 Sep 01; 92(5):1556-64. View in: Pubmed

      • Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998 Jun 15; 91(12):4496-503. View in: Pubmed

      • Metastic cancer of the unknown primary site. Harrison's Principles of Internal Medicine. 1998; 614-18. View in: Pubmed

      • Acute Leukemias. Oncology Board Review Manual. 1998; 3:1-16. View in: Pubmed

      • NCCN practice guidelines for the myelodysplastic syndromes. 1998; 12:53-80. View in: Pubmed

      • FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998 Jan; 18(1):84-7. View in: Pubmed

      • Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood. 1997 Oct 15; 90(8):3136-41. View in: Pubmed

      • Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet. 1997 Oct; 17(2):171-8. View in: Pubmed

      • Bryostatin 1: differentiating agent from the depths. Leuk Res. 1997 May; 21(5):399-401. View in: Pubmed

      • Diagnosis in Oncology. Leukemia cutis. J Clin Oncol. 1997 May; 15(5):2170-1. View in: Pubmed

      • CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47. View in: Pubmed

      • Mast cell leukemia and other mast cell neoplasms. Cancer Medicine. 1997; 2289-2834. View in: Pubmed

      • Diagnosis in Oncology. J Clin Oncol. 1997; 15:2170-71. View in: Pubmed

      • Harrison's Principles of Internal Medicine. 1997. View in: Pubmed

      • Case Records of the Massachusetts General Hospital. N Engl J Med. 1997; 337:1065-74. View in: Pubmed

      • Cancer Medicine Review. 1997. View in: Pubmed

      • Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55. View in: Pubmed

      • Kessler's legacy: unfinished reform. Science. 1996 Dec 06; 274(5293):1603-4. View in: Pubmed

      • Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996 Sep; 14(9):2486-94. View in: Pubmed

      • Fertility rates among lead workers and professional bus drivers: a comparative study. Ann Epidemiol. 1996 May; 6(3):201-8. View in: Pubmed

      • Corneal coloboma, aphakia and retinal neovascularization with anterior segment dysgenesis (Peters' anomaly). Ophthalmologica. 1996; 210(6):361-6. View in: Pubmed

      • Trials of 9-amino-20(S)-camptothecin. The Camptothecins: From Discovery to Patient. 1996; 803:247-255. View in: Pubmed

      • Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995 Jun 22; 332(25):1671-7. View in: Pubmed

      • A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15; 85(8):2025-37. View in: Pubmed

      • Uveitis associated with interleukin-3 and interleukin-6 therapy. Arch Ophthalmol. 1995 Apr; 113(4):408-9. View in: Pubmed

      • A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995 Apr 01; 85(7):1881-7. View in: Pubmed

      • Pathology and morphology of chronic leukemias and related disorders. Neoplastic Diseases of the Blood. 1995; 21-41. View in: Pubmed

      • Acute myeloid leukemia in adults. Clinical Oncology. 1995; 1959-76. View in: Pubmed

      • Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994 Dec; 12(12):2535-42. View in: Pubmed

      • Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res. 1994 Oct; 18(10):769-76. View in: Pubmed

      • Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood. 1994 Jun 15; 83(12):3437-40. View in: Pubmed

      • Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut. 1994 Mar; 35(3):363-8. View in: Pubmed

      • Neuroblastoma cell-mediated leukocyte chemotaxis: lineage-specific differentiation of interleukin-8 expression. Exp Cell Res. 1994 Mar; 211(1):1-5. View in: Pubmed

      • All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood. 1994 Jan 15; 83(2):490-6. View in: Pubmed

      • Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J Biol Chem. 1994 Jan 14; 269(2):872-8. View in: Pubmed

      • Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Advances in Bone Marrow Purging and Processing:4th International Symposium. Wiley-Liss. 1994; 47-63. View in: Pubmed

      • Harrison's Principles of Internal Medicine. 1994. View in: Pubmed

      • Metastatic cancer of the unknown primary site. Harrison's Prinicples of Internal Medicine. 1994; 1871-74. View in: Pubmed

      • Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Prog Clin Biol Res. 1994; 389:47-63. View in: Pubmed

      • A novel candidate autoantigen in a multiplex family with multiple sclerosis: prevalence of T-lymphocytes specific for an MBP epitope unique to myelination. J Neuroimmunol. 1993 Jul; 46(1-2):137-44. View in: Pubmed

      • Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by antagonists of adipogenesis. Mol Cell Biochem. 1993 Jun 9-23; 123(1-2):63-71. View in: Pubmed

      • Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol. 1993 Apr; 16(2):159-63. View in: Pubmed

      • All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells. Leukemia. 1993 Mar; 7(3):458-62. View in: Pubmed

      • Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):47-64. View in: Pubmed

      • The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):65-79. View in: Pubmed

      • Mast Cell Leukemia. Cancer Medicine. 1993; 2092-96. View in: Pubmed

      • Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992 Nov 15; 80(10):2604-9. View in: Pubmed

      • The association between the myelodysplastic syndromes and Crohn disease. Ann Intern Med. 1992 Oct 15; 117(8):661-2. View in: Pubmed

      • Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992 Jun; 10(6):948-53. View in: Pubmed

      • Hematopoietic growth factors and leukemia. Curr Opin Oncol. 1992 Feb; 4(1):33-44. View in: Pubmed

      • Acute myeloid leukemia. Current therapy in Hematology/Oncology. 1992; 63-68. View in: Pubmed

      • Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother. 1992; 35(4):277-82. View in: Pubmed

      • The association between the myelodysplastic syndromes and Chron disease. Ann Int Med. 1992; 117:661-2. View in: Pubmed

      • Case Records of the Massachusetts General Hospital (case 17). N Engl J Med. 1992; 326:1137-46. View in: Pubmed

      • Effect of picibabil (OK432) on neutrophil-mediated anti-tumor activity: Implication of monocyte-derived neutophil activating factors. Cancer Immunother. 1992; 35:277-82. View in: Pubmed

      • Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells. FEBS Lett. 1991 Dec 02; 294(1-2):73-6. View in: Pubmed

      • Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest. 1991 Aug; 88(2):571-7. View in: Pubmed

      • Harrison's Principles of Internal Medicine. 1991. View in: Pubmed

      • Expressino of the jun-B gene during induction of monocytic differentiation. Cell growth and differentiation. 1991; 2:43-9. View in: Pubmed

      • CSFs in combination with cytosine arabinoside, an inhibitor of DNA synthesis: potential strategies for the treatment of myeloid disorders. Biotechnol Ther. 1991; 2(3-4):269-83. View in: Pubmed

      • Expression of the jun-B gene during induction of monocytic differentiation. Cell Growth Differ. 1991 Jan; 2(1):43-9. View in: Pubmed

      • Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol. 1990 Dec; 144(6):1331-3; discussion 1333-4. View in: Pubmed

      • A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Leukemia. 1990 Dec; 4(12):843-7. View in: Pubmed

      • The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990 Nov; 8(11):1913-21. View in: Pubmed

      • Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites. Blood. 1990 Sep 15; 76(6):1225-32. View in: Pubmed

      • Age-related cognitive recovery after general anesthesia. Anesth Analg. 1990 Sep; 71(3):217-24. View in: Pubmed

      • Relation of urinary cotinine concentrations to cigarette smoking and to exposure to other people's smoke. Thorax. 1990 May; 45(5):356-61. View in: Pubmed

      • Prolymphocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):457-71. View in: Pubmed

      • Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem. 1990 Feb 25; 265(6):3320-3. View in: Pubmed

      • Angiotensin II inhibits luteinizing hormone-stimulated cholesterol side chain cleavage expression and stimulates basic fibroblast growth factor expression in bovine luteal cells in primary culture. J Biol Chem. 1990 Jan 05; 265(1):5-8. View in: Pubmed

      • Promylocytic leukemia. Hematology/Oncology Clinics of North America. 1990; 4:457-71. View in: Pubmed

      • Regulation of c-jun expression by phorbol esters and tumor necrosis factor. Molecular and Cellular Biology of Cytokines. 1990; 221-6. View in: Pubmed

      • Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J Biol Chem. 1989 Sep 05; 264(25):14653-61. View in: Pubmed

      • Detection of tumor necrosis factor gene expression at a cellular level in human acute myeloid leukemias. Leukemia. 1989 Jan; 3(1):51-6. View in: Pubmed

      • Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester. Mol Cell Biol. 1989 Jan; 9(1):252-8. View in: Pubmed

      • Lovastatin and rhabdomyolysis. Ann Intern Med. 1988 Oct 15; 109(8):682-3. View in: Pubmed

      • Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Aug; 72(2):739-44. View in: Pubmed

      • Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Jul; 72(1):208-13. View in: Pubmed

      • MRI of periprostatic venous plexus in staging of early prostatic carcinoma. Can Assoc Radiol J. 1988 Jun; 39(2):111-4. View in: Pubmed

      • Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988 Mar; 71(3):690-6. View in: Pubmed

      • Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987 Nov 15; 47(22):5846-52. View in: Pubmed

      • Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 1987 Jan; 69(1):187-91. View in: Pubmed

      • The treatment of myelodysplastic syndromes. Clin Haematol. 1986 Nov; 15(4):1081-107. View in: Pubmed

      • Further report of a prospective randomized trial comparing distal splenorenal shunt with end-to-side portacaval shunt. An analysis of encephalopathy, survival, and quality of life. Gastroenterology. 1985 Feb; 88(2):424-9. View in: Pubmed

      • Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection. Infect Immun. 1983 Jan; 39(1):198-201. View in: Pubmed

      • Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol. 1982 Oct; 54(5):527-30. View in: Pubmed

      • The significance of fibronectin in cryoprecipitation in rheumatoid arthritis and other diseases. J Rheumatol. 1982 Jul-Aug; 9(4):514-8. View in: Pubmed

      • Esophagogastrectomy using the auto suture EEA surgical stapling instrument. Ann Thorac Surg. 1980 Oct; 30(4):308-12. View in: Pubmed

      • A prospective randomized trial of the selective distal splenorenal shunt. Surg Gynecol Obstet. 1980 Jan; 150(1):45-8. View in: Pubmed

      • Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis. 1979 Dec; 140(6):881-9. View in: Pubmed

      • Massive lower gastrointestinal bleeding: an unusual complication of Crohn's disease. Can J Surg. 1978 Sep; 21(5):444-5. View in: Pubmed

      • Selection of operation in patients with bleeding esophageal varices. Can Med Assoc J. 1978 Feb 18; 118(4):369-72. View in: Pubmed

      • Toxic megacolon: results of emergency colectomy. Can J Surg. 1977 Jan; 20(1):36-8. View in: Pubmed

      • Surgical treatment of hydatid disease of the liver. Can J Surg. 1976 Sep; 19(5):416-20. View in: Pubmed

      • Survivors of cancer in childhood. Ann Intern Med. 1976 May; 84(5):551-3. View in: Pubmed

      • Familial colon cancer. Cancer. 1976 Feb; 37(2):946-8. View in: Pubmed

      • Melanocytoma. Arch Ophthalmol. 1975 Jul; 93(7):540-1. View in: Pubmed

      • Benign liver cell tumors. Classification and ultrastructural pathology. Cancer. 1973 Aug; 32(2):463-70. View in: Pubmed

      • Bronchial arterial circulation restored after reimplantation of canine lung. Can J Surg. 1970 Jul; 13(3):243-50. View in: Pubmed

      • Some observations on the cause of the gastric hypersecretion following portacaval shunt. Bull Soc Int Chir. 1968 Jul-Aug; 27(4):286-90. View in: Pubmed

      • The nature and source of a gastric secretagogue. Observations from the obstructed portal vein. Arch Surg. 1967 Oct; 95(4):606-8. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 1B-17 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 1B-17 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Richard M. Stone, MD

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights

      Back to Top